Document:

exv10w43

Exhibit 10.43

Confidential Materials omitted and filed separately with the

Securities and Exchange Commission. Asterisks denote omissions.

SUPPLY AND DISTRIBUTION AGREEMENT

     This Supply and Distribution Agreement (this “Agreement”), dated as of May 6, 2008, is between
Kawasumi Laboratories, Inc., a Japanese corporation with its offices at 3-28-15, Minami-Ohi,
Shinagawa-ku, Tokyo 140-8555, Japan and Medisystems Corporation, a Washington corporation with its
offices at 439 South Union Street, 5th Floor, Lawrence, Massachusetts 01843, U.S.A.
Reference should be made to Article 27 of this Agreement for definitions of capitalized terms used
herein.

     In consideration of the mutual promises made herein and other good and valuable consideration,
the receipt of which is hereby acknowledged, the parties hereto agree as follows:

ARTICLE 1

BACKGROUND

     1.1 KL manufactures disposable medical products and MDS sells and markets the Products in the
Territory (as described in Annex B).

     1.2 MDS manufactures disposable medical products and MDS sells BTL, AVF, BH, VN and NX used in
artificial kidney dialysis, as well as PHE and other products. MDS also manufactures or purchases
and sells Components, some of which are designed by MDS to be used in the Products. Such
Components will be sold or consigned to KL for incorporation into the Products in accordance with
this Agreement, and under some conditions, certain Components may be used or resold by KL for its
own products or markets.

     1.3 Pursuant to long-standing business relations, agreements and understandings, the Products
KL sells to MDS are manufactured by KL to the MDS design specifications and the KL process
specifications. It has been KL’s right and practice to delegate certain responsibilities to its
subsidiary, Kawasumi Laboratories (Thailand) Co., Ltd., and KL may continue to so delegate. Such
delegation shall not relieve KL of its responsibilities to assure each provision of this Agreement
is complied with in full.

     1.4 KL and MDS have entered into a certain Supply and Distribution Agreement dated as of
February 1, 2001, as amended on January 31, 2007, February 9, 2007, June 27, 2007, July 31, 2007,
August 30, 2007, September 26, 2007, October, 30, 2007, November 30, 2007, December 27, 2007,
January 30, 2008, February 29, 2008, March 31, 2008, and April 28, 2008 (collectively, the “2001
Agreement”). KL and MDS agree to have this Agreement supersede the 2001 Agreement with respect to
the supply and distribution of BTL and NX between the parties; provided, however, that the 2001
Agreement shall continue to be in full force and effect with respect to AVF, BH, VN and PHE, and
shall govern the supply and distribution thereof between the parties.

     1.5 In pursuance of this cooperation and in compliance with certain requirements of the FDA,
the parties have entered into the QA Agreement which governs certain aspects of the design and
manufacturing of the Products and the supply of Components.

 

 

ARTICLE 2

SPECIFICATIONS

     2.1 The Products and Components shall meet the Specifications and shall be subject to the
warranties set forth in Section 10.1, as such Specifications may, in accordance with the terms of
the QA Agreement, be amended or modified from time to time. MDS shall have the right to add or
replace the Codes set forth in Annex A hereto; provided that (a) the Product Price applicable to
the Codes to be added or replaced pursuant to the foregoing shall be agreed to by the parties
through good faith discussions prior to the placement of the first Shipment Order for such Codes by
MDS; and (b) MDS agrees that KL shall have no obligation to supply more than [**] Codes of
Streamline BTL at any given time during the Term. For clarification purposes, the aggregate number
of Streamline BTL Codes set forth in Annex A may exceed [**] Codes over the course of the Term, but
shall not exceed [**] Codes at any particular point in time during the Term.

     2.2 MDS shall provide KL with necessary materials for packaging and labeling of the Products
such as artwork, negative films and so on.

ARTICLE 3

PURCHASES AND SHIPMENTS

     3.1 Subject to the terms and conditions of this Agreement, KL shall manufacture the Products,
in quantities up to KL’s Supply Commitment, and all in accordance with the provisions of the QA
Agreement, the Specifications and the KL process specifications, and shall sell the Products to
MDS. MDS shall purchase the Products solely for resale in the Territory, provided that MDS, if it
sources NX from KL, may sell NX anywhere in the World. MDS shall not purchase BTL or
sub-assemblies thereof from any other third party other than KL except as provided in this
Agreement. MDS shall not sell the Products (other than NX) directly or indirectly to distributors
or end-users for use or resale outside of the Territory without KL’s prior written consent. Except
for the sale of Products from KL to MDS pursuant to the terms and conditions of this Agreement, KL
shall not (a) sell BTL or sub-assemblies thereof, directly or indirectly, for use or resale in the
U.S. to any party other than MDS without MDS’ prior written consent, or (b) sell Streamline BTL or
NX worldwide to any party other than MDS.

     3.2 MDS’ purchasing goal and purchasing commitments for BTL and NX during the Term shall be as
set forth in this Section 3.2.

	 	a.	 	MDS’ total purchasing goal for Products during the Initial Term
is [**] units of Products (“Initial Goal”). During the Initial Term, and
subject to the other terms and conditions contained herein, MDS hereby agrees
to purchase from KL a total quantity of Products at least equal to [**] percent
([**]%) of the Initial Goal (i.e., [**] units of Products) (such amount shall
be referred to herein as “Initial Purchase Commitment”).
	 
	 	b.	 	In the event MDS fails to place Shipment Orders for Products
during the Initial Term sufficient to meet its Initial Purchase Commitment,
upon expiration of the Initial Term, (i) KL may ship to MDS the quantity of

 

 

	 	 	 	Products short of the Initial Purchase Commitment (calculated by subtracting
the quantity of Products set forth in the Shipment Orders placed by MDS during
the Initial Term from the Initial Purchase Commitment) (the quantity of
Products of such shortfall shall be referred to herein as “Initial Shortfall”
and the shipments thereof by KL shall be referred to as “Initial Shortfall
Shipments”), and (ii) MDS shall accept and pay for the Products shipped in such
Initial Shortfall Shipments. KL shall notify MDS upon the expiration of the
Initial Term in the event the Initial Purchase Commitment is not met and of the
amount of the Initial Shortfall. In such notice, KL shall also request MDS to
provide KL with the Codes of Products and quantities thereof to be shipped in
the Initial Shortfall Shipment; provided, however, that the aggregate unit of
Products set forth in such notice shall be no less than the Initial Shortfall.
MDS shall have [**] business days following its receipt of such notice to
provide such information to KL, subject to Sections 3.2c and 3.2e. If MDS
fails to provide such information within such [**] business day period, or to
the extent the aggregate quantity of Products set forth in such information
provided by MDS is less than the Initial Shortfall, KL may, at its sole
discretion, select the Codes of Products and the quantities thereof to be
shipped in the Initial Shortfall Shipment up to the Initial Shortfall. The
Initial Shortfall Shipments shall be made in [**] equal monthly installments
during the [**]-month period immediately following the expiration of the
Initial Term, with each shipment constituting [**] of the Initial Shortfall.
For the avoidance of doubt, (x) MDS shall supply KL with the Components
necessary for KL to manufacture the Products to be shipped in the Initial
Shortfall Shipments if KL places Component Orders for such Products in
accordance with the terms and conditions of this Agreement, and (y) any
termination or expiration of this Agreement shall not terminate KL’s right to
make the Initial Shortfall Shipments and receive payment therefor from MDS, or
relieve MDS of its obligation to accept such Initial Shortfall Shipments and
pay KL for such Initial Shortfall Shipments.

	 	c.	 	Notwithstanding the Initial Purchase Commitment, MDS shall
place Shipment Orders for Streamline BTL to KL for an amount at least equal to
the amount calculated pursuant to the following (the “Initial Streamline
Purchase Commitment”): (i) if the aggregate amount of Streamline BTL sold to
[**] during the Initial Term is equal to or more than [**] units, the Initial
Streamline Purchase Commitment shall be [**] units; and (ii) if the aggregate
amount of Streamline BTL sold to [**] during the Initial Term is less than [**]
units, the Initial Streamline Purchase Commitment shall be [**] percent ([**]%)
of the aggregate amount of Streamline BTL sold to [**] during the Initial Term.
For clarification purposes, any Shipment Orders for Streamline BTL units used
for the purposes of confirming
MDS’ compliance with the Initial Streamline Purchase Commitment shall also
be counted towards the Initial Purchase Commitment and the unit 

 

 

	 	 	 	amount of
the Initial Streamline Purchase Commitment is not additive to the unit
amount of the Initial Purchase Commitment.

	 	d.	 	Upon request from KL, MDS shall disclose to KL information
regarding the Codes and respective quantities of Streamline BTL sold to [**]
during the Initial Term. MDS shall keep and maintain complete and accurate
books, records and accounts relating to its sale of Streamline BTL to [**], and
KL shall have the right, from time to time, to have an independent auditor
audit such books, records and accounts of MDS to verify MDS’ compliance with
the terms and conditions of this Section 3.2d. Any such audit shall be
conducted during the regular business hours of MDS, in such a manner so as not
to interfere with the normal business activities of MDS, and shall be at KL’s
expense; provided, however, that, if such audit reveals any material
discrepancies between the actual figures and reported figures of the Streamline
Products sold to [**] during the Initial Term, the cost of such audit shall be
borne by MDS. KL shall cause its independent auditor not to disclose any
information discovered in connection with this audit to any third party
(including KL) other than the information related to MDS’ sales of Products
which may be disclosed to KL hereunder consistent with the terms hereof.
	 
	 	e.	 	In the event (i) MDS fails to place Shipment Orders for
Streamline BTL during the Initial Term (or the Revised Initial Commitment Term,
if the Initial Streamline Purchase Commitment is revised pursuant to Section
3.2f) sufficient to meet its Initial Streamline Purchase Commitment, or (ii)
the audit set forth in Section 3.2d reveals any non-compliance with the Initial
Streamline Purchase Commitment, KL shall have the right to include the quantity
of Streamline BTL short of the Initial Streamline Purchase Commitment
(calculated by subtracting the quantity of Streamline BTL set forth in the
Shipment Orders placed by MDS during the Initial Term (or the Revised Initial
Commitment Term, if the Initial Streamline Purchase Commitment is revised
pursuant to Section 3.2f) from the Initial Streamline Purchase Commitment) in
the Initial Shortfall Shipments set forth in Section 3.2b.
	 
	 	f.	 	Notwithstanding anything set forth herein to the contrary, KL
agrees that, if MDS fails to renew its supply agreement for BTL with [**]
despite good faith efforts to negotiate such renewal, subject to Section 3.2j
and upon written notice to KL, MDS shall have the right, but not the
obligation, to revise its Initial Purchase Commitment and Initial Streamline
Purchase Commitment to an amount equal to the original Initial Purchase
Commitment and the original Initial Streamline Purchase Commitment multiplied
by the ratio of the period from the Effective Date until the end of the [**]
calendar month following the month in which such notice is received by KL (the
“Revised Initial Commitment Term”)
to the Initial Term. MDS shall fulfill such revised Initial Purchase
Commitment and revised Initial Streamline Purchase Commitment, by the

 

 

	 	 	 	expiration of the Revised Initial Commitment Term. In the event MDS fails
to place Shipment Orders for Products during the Revised Initial Commitment
Term sufficient to meet its revised Initial Purchase Commitment and/or its
revised Initial Streamline Purchase Commitment, upon expiration of the
Revised Initial Commitment Term, KL may ship to MDS the quantity of Products
short of the revised Initial Purchase Commitment and/or the revised Initial
Streamline Purchase Commitment in accordance with Sections 3.2b and 3.2e;
provided however, any reference to the Initial Term therein shall be
automatically deemed to be replaced with reference to the Revised Initial
Commitment Term, and any reference to the Initial Purchase Commitment and
the Initial Streamline Purchase Commitment therein shall automatically mean,
respectively, the Initial Purchase Commitment and the Initial Streamline
Purchase Commitment as revised pursuant to this Section 3.2f. In addition,
in the event MDS elects to exercise its rights pursuant to this Section 3.2f
to revise the Initial Purchase Commitment and the Initial Streamline
Purchase Commitment:

	 	1.	 	immediately upon the issuance of the notice by
MDS set forth in this Section 3.2f, any and all references to the
Initial Purchase Commitment and/or the Initial Streamline Purchase
Commitment contained in this Agreement shall mean respectively, the
Initial Purchase Commitment and the Initial Streamline Purchase
Commitment as revised pursuant to this Section 3.2f;
	 
	 	2.	 	all obligations of KL related to the Supply
Commitment shall terminate as of the expiration of the Revised Initial
Commitment Term;
	 
	 	3.	 	notwithstanding Section 3.1, any restriction on
KL regarding the sale of BTL (including subassemblies thereof) in the
U.S., directly or indirectly, for use or resale in the U.S. shall be
terminated as of the expiration of the Revised Initial Commitment Term;
	 
	 	4.	 	for any BTL which is a work-in-progress as of
the date on which KL receives the notice by MDS set forth in this
Section 3.2f, in accordance with the other terms and conditions of this
Agreement, (i) KL shall complete the manufacture of such BTL within
[**] months of such notice and deliver such BTL to MDS, (ii) MDS shall
supply KL with the Components necessary for KL to complete the
manufacture of such BTL, (iii) MDS shall accept and pay for such BTL,
and (iv) any termination or expiration of this Agreement shall not
terminate the rights and obligations of KL and MDS under this Section
3.2f.4, including, without limitation, KL’s right to receive payment
for such BTL from MDS; and

 

 

	 	5.	 	this Agreement shall terminate upon the
expiration of the Initial Term.

	 	g.	 	The parties shall discuss in good faith and agree to MDS’ total
purchasing goal for Products during each Renewal Term (the “Renewal Goal”) no
later than [**] months prior to the expiration of the Term then in effect.
During each Renewal Term, and subject to the other terms and conditions
contained herein, MDS hereby agrees to purchase from KL a total quantity of
Products at least equal to [**] percent ([**]%) of the Renewal Goal (such
amount shall be referred to herein as the “Renewal Purchase Commitment”).
	 
	 	h.	 	In the event MDS fails to place Shipment Orders for Products
during the applicable Renewal Term sufficient to meet its Renewal Purchase
Commitment, upon expiration of the Applicable Renewal Term, (i) KL may ship to
MDS the quantity of Products short of the Renewal Purchase Commitment
(calculated by subtracting the quantity of Products set forth in the Shipment
Orders placed by MDS during such Renewal Term from the Renewal Purchase
Commitment) (the quantity of Products of such shortfall shall be referred to
herein as the “Renewal Shortfall” and the shipments thereof by KL shall be
referred to as the “Renewal Shortfall Shipments”), and (ii) MDS shall accept
and pay for the Products shipped in such Renewal Shortfall Shipments. KL shall
notify MDS upon the expiration of the applicable Renewal Term in the event the
Renewal Purchase Commitment is not met and of the amount of the Renewal
Shortfall. In such notice, KL shall also request MDS to provide KL with the
Codes of Products and quantities thereof to be shipped in the Renewal Shortfall
Shipment; provided, however, that the aggregate unit of Products set forth in
such notice shall be no less than the Renewal Shortfall. MDS shall have [**]
business days following its receipt of such notice to provide such information
to KL. If MDS fails to provide such information within such [**] business day
period, or to the extent the aggregate quantity of Products set forth in such
information provided by MDS is less than the Renewal Shortfall, KL may, at its
sole discretion, select the Codes of Products and the quantities thereof to be
shipped in the Renewal Shortfall Shipment up to the Renewal Shortfall. The
Renewal Shortfall Shipments shall be made in [**] equal monthly installments
during the [**]-months period immediately following the expiration of the
applicable Renewal Term, with each shipment constituting [**] of the Renewal
Shortfall. For the avoidance of doubt, (x) MDS shall supply KL with the
Components necessary for KL to manufacture the Products to be shipped in the
Renewal Shortfall Shipments if KL places Component Orders for such Products in
accordance with the terms and conditions of this Agreement, and (y) any
termination or expiration of this Agreement shall not terminate KL’s right to
make the Renewal Shortfall Shipments and receive payment therefor from MDS, or
relieve MDS of its obligation to

 

 

	 	 	 	accept such Renewal Shortfall Shipments and pay KL for such Renewal
Shortfall Shipments.

	 	i.	 	If the parties cannot agree on a Renewal Goal for the Renewal
Term immediately following the expiration of the Term then in effect (the
“Following Renewal Term”) no later than [**] months prior to the expiration of
the Term then in effect, the Renewal Goal for the Following Renewal Term shall
be determined in accordance with the following terms and conditions of this
Section 3.2i. If MDS agrees to accept a Renewal Goal for the Following Renewal
Term which is equal to or more than (x) [**] percent ([**]%) of the Initial
Goal, if the Following Renewal Term is the first Renewal Term under this
Agreement, or (y) [**] percent ([**]%) of the Renewal Goal of the then current
Renewal Term, if the Following Renewal Term is the second or any subsequent
Renewal Term, such figure shall become the Renewal Goal for the Following
Renewal Term. If MDS does not accept the Renewal Goal set forth in the
foregoing sentence, then the Renewal Goal for the Following Renewal Term shall
be reduced to [**] percent ([**]%) of the Renewal Goal then in effect;
provided, however, in such event, this Agreement shall terminate upon the
expiration of such Following Renewal Term.
	 
	 	j.	 	In any given consecutive [**] month period during the Initial
Term, MDS agrees to place monthly Shipment Orders that, in the aggregate, will
comprise no less than [**] percent ([**]%) and no more than [**] percent
([**]%) of the Initial Goal (the “Initial Maximum Order Quantity”). By way of
example only, if the Initial Goal for Products is [**] units of Products, MDS
shall place [**] consecutive monthly Shipment Orders, in any given [**] month
period during the Initial Term, that, in the aggregate, is no less than [**]
units of Products or more than [**] units of Products. Notwithstanding the
foregoing, KL agrees that, if MDS provides notice of the quantity to be ordered
in a particular calendar month no later than [**] months prior to the beginning
of such calendar month, MDS may exceed the Initial Maximum Order Quantity for
such calendar month, and KL shall use commercially reasonable efforts to supply
the quantity in excess of the Initial Maximum Order Quantity set forth in such
notice.
	 
	 	k.	 	In any given consecutive [**] month period during any Renewal
Term, MDS agrees to place monthly Shipment Orders that, in the aggregate, will
comprise no less than [**] percent ([**]%) and no more than [**] percent
([**]%) of the Renewal Goal for such Renewal Term (the “Renewal Maximum Order
Quantity”). By way of example only, if the Renewal Goal for Products is [**]
units of Products, MDS shall place [**] consecutive monthly Shipment Orders, in
any given [**] month period during the applicable Renewal Term, that, in the
aggregate, is no less than [**] units of Products or more than [**] units of
Products. Notwithstanding the foregoing, KL agrees that, if MDS provides
notice of the quantity to be ordered in a particular calendar month no later
than [**]

 

 

	 	 	 	months prior to the beginning of such calendar month, MDS may exceed the
Renewal Maximum Order Quantity for such calendar month and KL shall use
commercially reasonable efforts to supply the quantity in excess of the
Renewal Maximum Order Quantity set forth in such notice.

	 	l.	 	KL agrees to sell to MDS a total quantity of Products no less
than [**] percent ([**]%) of the Initial Goal and any Renewal Goal (“Supply
Commitment”).

     3.3 In order to facilitate the orderly forecasting of needs and the ordering, manufacturing
and shipping of Products, the parties agree to follow the following procedures:

	 	a.	 	On or prior to the [**] day of each month (“Forecast Date”)
during the Term, MDS shall provide KL with the following:

	 	1.	 	a forecast (the “First MDS Forecast”) of MDS
orders to be placed [**] days from the Forecast Date;
	 
	 	2.	 	a revised forecast of MDS orders to be placed
[**] days from the Forecast Date; and
	 
	 	3.	 	a further revised forecast (the “Final MDS
Forecast”) of MDS orders to be placed by the [**] day of the subsequent
month.

	 	b.	 	Based on the Final MDS Forecast the previous month, on or prior
to the [**] day of each month during the Term, MDS shall provide KL with a
Shipment Order consistent with the Purchase Commitments and Sections 3.2j and
3.2k. The Shipment Order shall set forth requested delivery dates for the
Products of, (i) in the case where the seaport of entry into the U.S. set forth
in the Shipment Order is located on the west coast of the U.S., no earlier than
[**] days after the Shipment Order Date and no later than [**] days after the
Shipment Order Date, and (ii) in the case where the seaport of entry into the
U.S. set forth in the Shipment Order is not located on the west coast of the
U.S., no earlier than [**] days after the Shipment Order Date and no later than
[**] days after the Shipment Order Date (the duration between the earliest and
latest date on which the requested delivery date may be set forth in the
Shipment Order shall be referred to herein as the “Shipment Period”). For
purposes of this Agreement, the “Shipment Order Date” means the date the
applicable Shipment Order is placed by MDS, or the [**] day of the month on
which the Shipment Order is placed, whichever is later.
	 
	 	c.	 	Based on the foregoing, KL shall purchase or produce components
(including the Components) necessary to manufacture and deliver the Products
during the Shipment Period. On or prior to the Forecast Date during the Term,
KL shall provide MDS with the foregoing:

 

 

	 	1.	 	a forecast (the “First KL Forecast”) of KL
orders for Components to be placed [**] days from the Forecast Date;
	 
	 	2.	 	a revised forecast of KL orders to be placed
[**] days from the Forecast Date; and
	 
	 	3.	 	a further revised forecast (the “Final KL
Forecast”) of KL orders to be placed by the [**] day of the subsequent
month.

	 	d.	 	Based on the Final KL Forecast the previous month, on or prior
to the [**] day of each month during the Term, KL shall provide MDS with its
Component Order for such month. The Component Order shall set forth requested
delivery dates for the Components of no earlier than [**] days after the
Component Order Date and no later than [**] days after the Component Order
Date. For purposes of this Agreement, the “Component Order Date” means the
date the applicable Component Order is placed by KL, or the [**] day of the
month on which the Component Order is placed, whichever is later.

The parties recognize that some Components (including packaging and labeling) may
become unusable if not incorporated into Products within a finite period of time
(“Dead Stock”). Accordingly, if KL produces or purchases Components based on the
First MDS Forecast and such Components are not, because the Products ordered in the
Shipment Orders are less than the First MDS Forecast, timely incorporated in the
Products and become Dead Stock, KL shall invoice MDS and MDS shall pay KL for the
cost of such Dead Stock. If KL does not ship Products during the applicable
Shipment Period, and such failure is not excused by an event described in Section
3.5, KL shall ship such Products as soon as possible, by airfreight at KL’s sole
expense, if so requested by MDS. KL and MDS shall discuss and exchange additional
forecasting and production scheduling information in order to minimize variances in
KL’s production and MDS’ inventories throughout the Term. The total quantity of
Products in MDS’ Shipment Orders shall approximately equal the total quantity of
Products in the relevant Final MDS Forecast unless a variance has been accepted by
KL. Similarly, the total quantity of Components in KL’s Component Orders shall
approximately equal the total quantity of Components in the relevant Final KL
Forecast unless a variance has been accepted by MDS.

     3.4 All sales of Products to MDS under this Agreement shall be subject to the provisions of
this Agreement and shall not be subject to the terms and conditions contained in any Shipment Order
of MDS, or confirmation or invoice of KL, except insofar as any such Shipment Order, confirmation
or invoice establishes (a) the quantity of Products ordered for shipment, and (b) the locations in
the U.S. to which such Products shall be delivered (the “Locations”) and the seaport of entry into
the U.S. for such Product shipments.

     3.5 KL assumes no liability and shall not be liable to MDS for any failure to fill or delay in
filling Shipment Orders received from MDS or to fulfill any Supply Commitment to the

 

 

extent of any cause beyond the control of or occurring without the fault of KL including but
not limited to strikes, lockouts (but only if resulting from worker sabotage, vandalism or similar
action), floods, fires, earthquakes, accidents, delays in the delivery of raw materials, parts or
completed merchandise by the supplier thereof. For the purposes of this Section 3.5, FDA actions
caused by the fault of KL are deemed to be within the control of KL. In the event of any delay
caused by any of the foregoing, KL shall use reasonable commercial efforts to fulfill MDS’ orders
in a timely fashion. KL shall notify MDS if it anticipates any potential delay in the filling of
any of MDS’ Shipment Orders caused by any of the foregoing.

     3.6 MDS assumes no liability and shall not be liable to KL for any failure to place Shipment
Orders, deliver Components or to fulfill any Purchase Commitment to the extent of any cause beyond
the control of or occurring without the fault of MDS including but not limited to strikes, lockouts
(but only if resulting from worker sabotage, vandalism or similar action) floods, fires,
earthquakes, accidents, delays in the delivery of raw materials, parts or competed merchandise by
the supplier thereof. In the event of any delay caused by any of the above, MDS shall use
reasonable commercial efforts to fulfill Component Orders and/or to place Shipment Orders in a
timely fashion. MDS shall notify KL if it anticipates any potential delay in the filling of any
Component Order or in placing Shipment Orders caused by any of the foregoing.

     3.7 Notwithstanding Sections 3.2 and 3.3, MDS may be relieved of its obligations with respect
to any specific Shipment Order, Component Order, or Purchase Commitment in whole or in part, at
MDS’ option, should KL be in material breach of this Agreement and if such breach is uncured within
ninety (90) days after KL receives notice from MDS of such breach, or should a delay under Section
3.5 occur and if such delay is uncured within ninety (90) days after MDS receives notice from KL of
such delay.

     3.8 Notwithstanding Sections 3.2 and 3.3 KL may be relieved of its obligations with respect to
any specific Shipment Order, Component Order, or Supply Commitment in whole or in part, at KL’s
option, should MDS be in material breach of this Agreement and if such breach is uncured within
ninety (90) days after MDS receives notice from KL of such breach, or should a delay under Section
3.6 occur and if such delay is uncured within ninety (90) days after KL receives notice from MDS of
such delay.

     3.9 MDS shall maintain and keep MDS inventories of the Products in accordance with then
applicable Purchase Commitment and the Final MDS Forecast provided in Section 3.3.

     3.10 MDS shall submit to KL each calendar quarter a report about the market situation of the
Products in the Territory including the tendency of the market, activities of third parties and
other remarkable changes in the market.

ARTICLE 4

SHIPMENT OF THE PRODUCTS/COMPONENTS

     4.1 KL will ship the Products properly ordered in accordance with Article 3 to the Locations
at the Product Prices. MDS will ship the Components to the location set forth in the applicable
Component Order and at the prices listed in Annex A.

 

 

     4.2 KL shall prepare and send by facsimile to MDS a packing list, invoice and bill of lading
for each shipment of the Products. KL shall notify MDS if any shipment will not be made within the
Shipment Period applicable to a Shipment Order. MDS shall prepare and send to KL a packing list,
invoice and bill of lading for each shipment of the Components.

ARTICLE 5

PRICES

     5.1 Except as otherwise specified herein, KL will sell the Products to MDS and MDS agrees to
purchase the Products from KL, and MDS will sell the Components to KL and KL agrees to purchase the
Components from MDS.

     5.2 The prices of the Products shall be as listed on Annex A, which may be revised from time
to time upon agreement of the parties, and may be adjusted pursuant to Sections 5.3, 5.4 and 5.5
(the “Product Prices”). The Product Prices are quoted as FOB Bangkok. Freight costs for
delivering Products to the Locations, as set forth in the chart for ocean freight cost for 40
feet/20 feet/LCL attached hereto as Annex C (the “Freight Costs”), shall be added to the Product
price. If MDS requests airfreight, and if KL is not obliged to pay for such airfreight under the
provisions of Section 3.3, 10.2 or 14.2, KL shall invoice MDS at the Product Prices, and MDS shall
bear the costs related to such airfreight. If KL is obliged to pay the airfreight under the
provisions of Section 3.3, 10.2 or 14.2, KL shall bear the costs related to such airfreight and
invoice MDS at the Product Prices plus the Freight Costs.

     5.3 Unless otherwise adjusted pursuant to the express provisions of this Agreement, the
Product Prices shall be as listed on Annex A, so long as the inter-bank Thai Baht to US$ exchange
rate as reported by the Bank of Thailand, Average Buying Rates, Telex Transfer on the date such
Shipment Order is placed (the “Baht/US$ Exchange Rate”) is at or above [**] Baht per US$1.00
(“Minimum Exchange Rate”) and at or below [**] Baht per US$1.00 (“Maximum Exchange Rate”). If, at
any time during the Term, the Baht/US$ Exchange Rate is lower (i.e., stronger) than the Minimum
Exchange Rate (e.g., [**] Baht per US$1.00) then the Product Prices for such Shipment Order shall
be increased by [**] ; provided, however, that such ratio shall be applied against the [**]. By
way of example only, [**]/unit. If, however, at any time during the Term, the Baht/US$ Exchange
Rate is higher (i.e., weaker) than the Maximum Exchange Rate (e.g., [**] Baht per US$1.00), then
the Product Prices for such Shipment Order will be decreased by [**]; provided, however, that such
ratio shall be applied against the [**]. By way of example only, [**]/unit. The price of the
Products calculated in accordance with this Section 5.3 shall be rounded up to the nearest ten
thousandth of a U.S. dollar.

     5.4 In addition to Section 5.3, the Product Prices shall be adjusted according to the formula
set forth below in the event there is a [**] percent ([**]%) or greater increase or decrease in the
price charged to KL by KL’s suppliers for unprocessed raw materials of polyvinyl chloride of like
quantity and quality for the main tubes of the Products (excluding any freight, duties or other
costs related to the shipment of such raw materials from the supplier to KL) (the “PVC Price”),
from the PVC Price charged to KL as of September 30, 2007 (the “Base PVC Price”). For purposes of
this Agreement, (i) the PVC Price applicable to the Products to be shipped to MDS in the relevant
Shipment Order shall be referred to as the “Current PVC Price”, (ii) the ratio of increase of the
Current PVC Price to the Base PVC Price shall be referred to as

 

 

the “PVC Price Increase Ratio” (by way of example only, [**] (by way of example only, [**] (by
way of example only, [**]. The price of the Products calculated in accordance with this Section
5.4 shall be rounded up to the nearest ten thousandth of a U.S. dollar.

	 	a.	 	In the event of a [**] percent ([**]%) or greater increase from
the Base PVC Price, the Product Price shall be increased by a ratio calculated
by [**]/unit.
	 
	 	b.	 	In the event of a [**] percent ([**]%) or greater decrease from
the Base PVC Price, the Product Price shall be decreased by a ratio calculated
by [**]/unit.
	 
	 	c.	 	Upon request from MDS, KL shall disclose to MDS information
regarding the then current PVC Price Increase Ratio and the PVC Price Decrease
Ratio. Notwithstanding anything herein to the contrary, in no event shall KL
be obligated to disclose to MDS any information related to the costs of the
Products other than the PVC Price Increase Ratio and the PVC Price Decrease
Ratio, including, without limitation, the PVC Price, Base PVC Price, Current
PVC Price and PVC Cost Ratio.
	 
	 	d.	 	MDS shall have the right, from time to time, to have an
independent auditor audit the books, records and accounts of KL to verify that
the prices set forth in KL’s invoices are consistent with the terms and
conditions of this Section 5.4. Any such audit shall be conducted during the
regular business hours of KL, in such a manner so as not to interfere with the
normal business activities of KL, and shall be at MDS’ expense; provided,
however, that, if such audit reveals material discrepancies between the actual
figures and reported figures for the PVC Price Increase Ratio and/or the PVC
Price Decrease Ratio, the cost of such audit shall be borne by KL. MDS shall
cause its independent auditor not to disclose any information related to the
costs of the Products, including, without limitation, the PVC Price, Base PVC
Price, Current PVC Price and PVC Cost Ratio, to any party (including MDS) other
than the disclosure of the PVC Price Increase Ratio and the PVC Price Decrease
Ratio to MDS.

     5.5 In the event the Product Prices may be adjusted pursuant to both Sections 5.3 and 5.4, the
parties agree that the Product Prices shall be adjusted first by applying the terms and conditions
of Section 5.3, and then shall be further adjusted by applying the terms and conditions of Section
5.4.

     5.6 MDS and KL further agree that the Product Prices for Streamline BTL shall be reduced as
follows and replaced by the price after such reduction amount, in the event the following
modifications to the Specifications of such Products are implemented into the Streamline BTL. All
Components to be pre-assembled in accordance with the changes to the Specifications set forth below
shall be provided by MDS to KL, free of charge, in accordance with the other terms and condition of
this Agreement.

 

 

	 	 	 
	Changes to the Specifications	 	Amount to be Reduced from Product Price
	Locksite and cap for the main tube
pre-assembled by MDE

	 	$[**] per unit
	Locksite and cap for IV set
pre-assembled by MDE

	 	$[**] per unit
	Change P-2 chamber to parts
supplied by MDE, chamber and turbo
cap pre-assembled by MDE

	 	$[**] per unit

ARTICLE 6

PAYMENT

     6.1 The terms of payment for the Products purchased by MDS and for the Components purchased by
KL under this Agreement shall be D/A (Documents against Acceptance) at [**] days from KL’s or MDS’
bill of lading date. With respect to this Section 6.1, each party shall send all necessary
documents for payment to the other party within [**] days from KL’s or MDS’ bill of lading date.
Any amounts not paid within [**] days of the bill of lading date shall be subject to a service
charge until paid equal to the lesser of [**] percent ([**]%) per month or the maximum rate allowed
by law. If full payment is not received by KL or MDS within [**] days of KL’s or MDS’ bill of
lading date, MDS or KL respectively shall be considered to be in material breach of this Agreement
and subject to the provisions of Section 12.1.

ARTICLE 7

MDS SUPPLIED COMPONENTS; PRODUCT CHANGES

     7.1 During the Term, MDS will sell and/or consign to KL the Components to be incorporated by
KL, in accordance with its then current process specifications, into the Products. Except as
expressly provided in Annex B or agreed by the parties, KL shall not incorporate any Components
into any other product nor resell any of the Components for sale or resale by any third party.

     7.2 KL shall maintain and keep KL inventories of the Components in accordance with the First
MDS Forecast provided by MDS in accordance with Section 3.3, but shall not produce or purchase
components with respect to any prospective Shipment Order prior to receiving the First MDS Forecast
in respect to such prospective Shipment Order.

     7.3 During the Term, MDS may require new Product designs to meet the competitive requirements
of its market and/or to meet any of its Purchase Commitments. MDS may design new Components, Codes
and Products and cause changes to be made to the Specifications, in accordance with the provisions
of Section 2.1 of this Agreement and the QA Agreement. KL will have the right, in good faith to
reject such new Specifications based only on lack of capacity to produce such new Specifications.
And, in any event, KL will have the right to adjust the

 

 

Product Prices based on such changed Specifications only to the extent that such changes
increase or decrease KL’s true cost of production. KL will cooperate with MDS in incorporating
such new Components, Codes and Products and changes into the Specifications for the Products. To
assist KL in production planning, MDS will meet at least [**] yearly with KL for the purpose of
describing any current MDS design projects that, within the succeeding twelve months, are likely to
produce a change in the Specifications and the introduction of new Components for the Products.
During the Term, KL may make changes in its process specifications and/or components supplied by
KL, all in accordance with the provisions of the QA Agreement. At least [**] yearly, KL shall
advise MDS, in accordance with Section 5.3 of the QA Agreement, of any prospective KL process
changes that, within the succeeding twelve (12) months, are likely to produce a change in KL’s
process specifications and/or of the components supplied by KL or to affect the quality of the
Products.

     7.4 Whenever MDS adds a new Specifications for Components or Products, KL has a first right
(prior to that of any third party) to bid on the supply of such Components. KL’s bid may be based
on MDS’ design and/or KL’s alternative design, if any, but the content of the Specifications shall
remain within the sole discretion of MDS. KL and MDS may negotiate which party shall supply such
Components by taking into consideration cost, quality, quantity and patent issues. Nothing herein
shall imply any license or obligation to license the patents of one party to the other and no
license shall be granted unless the parties mutually so agree in a separate license agreement.

     7.5 At reasonable intervals, KL may, with prior notice to and with the prior consent of MDS
which consent shall not unreasonably be withheld, send its representatives to MDS to audit the
procedures or processes used in manufacturing the Components. At reasonable intervals, MDS may
with prior notice to and with the prior consent of KL, which consent shall not unreasonably be
withheld, send its representatives (including representatives of its customers) to KL to audit the
procedures or processes used in manufacturing the Products.

ARTICLE 8

REGULATORY RESPONSIBILITY

     8.1 KL shall be responsible, at its expense, for complying with all of its obligations under
the provisions of the QA Agreement. Failure to manufacture the Products in compliance with the QA
Agreement shall be considered a breach of this Agreement by KL as to which MDS’ exclusive remedies
shall be to terminate this Agreement under Section 12.1, to terminate any specified Shipment
Order(s) under Section 3.7 and/or to reduce its outstanding Shipment Orders, any such termination
or reduction to be credited on a unit basis toward the applicable Purchase Commitment.

     8.2 MDS shall be responsible, at its expense, for complying with all of its obligations under
the provisions of the QA Agreement relating to the design, sale or use of the Products, including
but not limited to obtaining authorization under Section 510(k) of the “Act”.

     8.3 Except as provided in this Agreement, MDS shall not use any trade name, trademark or logo
owned or controlled by KL, or any trademark, trade name or logo confusingly similar therewith,
during or after the Term. KL shall not use any trade name, trademark or logo

 

 

of MDS, or any trade name, trademark or logo confusingly similar therewith, without obtaining
MDS’ prior written permission during or after the Term.

ARTICLE 9

GUARANTEE

     9.1 All Products sold to MDS under this Agreement are hereby guaranteed by KL, as of the time
the title to the Products is transferred to MDS, to be not adulterated or misbranded within the
meaning of the Act, and not an article which may not, under the provisions of Section 510(i) of the
Act, be introduced into interstate commerce. If KL breaches this guarantee with respect to any lot
of Product, MDS may immediately return to KL, at KL’s expense, any Products of such lot received by
MDS. At MDS’ option, KL either will credit MDS for such Products, or pay to MDS any monies paid by
MDS for the Products that breach this guarantee. If KL breaches this guarantee, then to the extent
that MDS terminates or reduces Shipment Orders to allow for replacement products, such termination
or reduction will be credited on a unit basis toward the applicable Purchase Commitment. The
foregoing, along with Article 14, represents MDS’ sole and exclusive remedy for a KL breach of this
guarantee. In no event will KL be deemed to be in breach of this guarantee to the extent KL’s
failure to meet the guarantee is caused by KL’s adherence to the Specifications, proper use of the
Components or compliance with MDS instructions regarding the Specifications or the Components.
Notwithstanding the foregoing, KL shall in all events manufacture the Products in accordance with
the KL process specifications.

ARTICLE 10

WARRANTY

     10.1 KL warrants the Products sold to MDS under this Agreement are, as of the time title is
transferred to MDS, in compliance with the Specifications and the QA Agreement and made in
accordance with the then applicable KL process specifications. KL warrants that its parts and
process specifications are reasonably appropriate for the production of Products which insofar was
they relate solely to said parts and process specifications (and not in any way related to the
Specifications and/or the Components supplied by MDS to KL in connection with the production of the
Products) are merchantable and fit for resale in the Territory (subject to the end-users’ proper
usage thereof and assuming that the Products are used in connection with their intended purpose,
e.g., for use in artificial kidney dialysis). MDS warrants that the Components sold to KL under
this Agreement are, as of the time title is transferred to KL, in compliance with the
Specifications and the QA Agreement and further the Components are reasonably appropriate for the
production of the Products which insofar as they relate solely to said Components and the
Specifications (and not in any way related to the process specifications and any parts supplied by
KL in connection with the production of the Products) are merchantable and fit for resale in the
Territory (subject to the end-users’ proper usage thereof and assuming that the Products are used
in connection with their intended purpose, e.g., for use in artificial kidney dialysis).

     10.2 MDS acknowledges and agrees that, except for the provisions of Section 10.3 , KL’s sole
responsibility to MDS in the case of breach of the foregoing warranty shall be for KL, by mutual
agreement of MDS and KL, to repair or replace the Products with respect to which such warranty is
breached, or at MDS’ election for KL to return to MDS all payments made by

 

 

MDS to KL with respect to such Products or to credit MDS in the amount of all payments made by
MDS to KL with respect to such Products. In no event shall KL be liable for MDS’ loss of profits,
loss of use, or incidental, consequential or special damages of any kind even if KL has been
advised by MDS of any possibility thereof.

     10.3 KL hereby indemnifies and agrees to hold MDS harmless from and against all claims,
liability, damage, cost or expense of MDS, including its reasonable attorney’s fees paid to third
parties arising out of, or in connection with, or as a result of, to the extent based upon the
failure of any of the Products to meet the warranty set forth in Section 10.1 at the time of
delivery to MDS and such failure is not due to any failure of a Component to meet the
Specifications, provided MDS promptly notifies KL of any such claim, KL has control over the
defense of such claim and MDS provides reasonable cooperation. In order to discharge KL’s
obligations under this Section 10.3, KL and MDS agree that MDS shall obtain and keep in force
during the Term, product liability insurance with a limit of liability for the Territory of not
less than US$20 million, and shall name KL as an additional insured. KL shall reimburse MDS for
the cost of such insurance at the rate of US$3.66 per US$1,000 of MDS purchases from KL.

     10.4 MDS shall indemnify and hold KL harmless from and against all claims, liability, damage,
cost or expense of KL, including its reasonable attorney’s fees to the extent based upon: (a) any
false or misleading product claims, representations, descriptions or other statements, whether oral
or written, made or alleged to be made by MDS or its representatives in any advertising, publicity,
promotion or sale of any of the Products, and (b) any product claim arising out of, based on, or
caused by negligent handling of the Products by MDS.

     10.5 The KL warranties set forth herein (including without limitation the warranty set forth
in Section 10.1 that the Products sold to MDS under this Agreement are, as of the time title is
transferred to MDS, in compliance with KL’s then applicable process specifications) are exclusive
and in lieu of all other warranties, whether express or implied, including the implied warranties
of merchantability, infringement, and fitness for a particular purpose. The MDS warranties set
forth herein are exclusive and in lieu of all other warranties, whether express or implied,
including the implied warranties of merchantability, infringement, and fitness for a particular
purpose.

ARTICLE 11

TERM OF AGREEMENT

     11.1 The term of this Agreement (the “Term”) shall be from the Effective Date until January
31, 2010 (the “Initial Term”); provided that such Term shall automatically be renewed for
subsequent periods of one (1) year (collectively, the “Renewal Term”) unless either party gives
notice of termination no later than six (6) months prior to the date on which this Agreement would
otherwise terminate.

 

 

ARTICLE 12

TERMINATION

     12.1 Either party may terminate this Agreement for any material breach of it by the other
party, by giving ninety (90) days written notice to the other party, if such breach shall, as of
the expiration of said ninety (90) day period, remain uncured.

     12.2 Either party shall have the right at its option to terminate this Agreement effective
immediately upon giving written notice to the other party in the event of:

	 	a.	 	appointment of a trustee, receiver or other custodian for all
or substantially all of the property of such other party, or for any lesser
portion of such property if the result is materially and adversely to affect
the ability of such other party to fulfill its affirmative or negative
obligations hereunder;
	 
	 	b.	 	a judicial finding that such other party is insolvent or
bankrupt;
	 
	 	c.	 	the filing of a petition in bankruptcy for itself by such other
party or a decision that bankruptcy proceedings will be instituted with respect
to such other party based on a petition filed by a third party;
	 
	 	d.	 	an assignment of a substantial part of the assets of such other
party for the benefit of creditors;
	 
	 	e.	 	an attachment of a substantial part of the assets of such other
party for the benefit of creditors; or
	 
	 	f.	 	the dissolution or liquidation of a party.

     12.3 If either party here suffers any event of the type enumerated in Section 12.2, it shall
immediately notify the other party in writing of the occurrence of such event.

ARTICLE 13

EFFECT OF TERMINATION

     13.1 No termination of this Agreement, other than by reason of breach of this Agreement by MDS
will relieve KL from its obligation to deliver all Products ordered by any properly placed Shipment
Order of MDS, nor will any termination, other than by reason of breach of this Agreement by KL,
relieve MDS from accepting and paying for all Products ordered by MDS under any properly placed
Shipment Order issued by MDS or relieve MDS of its obligations pursuant to Section 3.3. The rights
and obligations related to the Initial Shortfall Shipments under Sections 3.2b and 3.2e, the rights
and obligations related to the work-in-progress BTL under Section 3.2f.4, the rights and
obligations related to the Renewal Shortfall Shipments under 3.2h, and the indemnification
obligations under Article 10 shall survive the termination of this Agreement.

 

 

ARTICLE 14

PRODUCT RECALL

     14.1 In the event that it shall be deemed necessary by KL or MDS to recall any of the Products
sold by MDS because the Products are believed to violate any provision of any law, the guarantees
provided in Section 9.1 or the warranties provided in Section 10.1, and if such Products have
already been delivered to the Location, KL and MDS shall, subject to Section 14.4 below, share
equally all out-of-pocket costs and expenses of such recall, including, without limitation, refunds
to customers for recalled Products but only in an amount not to exceed the sum of the following
items:

	 	a.	 	the purchase price paid by MDS to KL for the recalled Products;
	 
	 	b.	 	the freight paid by MDS associated with the shipment of
affected Products from the Locations;
	 
	 	c.	 	the cost of notifying customers;
	 
	 	d.	 	the costs associated with the shipment of recalled Products
from customers to MDS; and
	 
	 	e.	 	the cost of shipping replacement Products to customers.

MDS may immediately return any recalled Products to KL for rework or credit.

     14.2 If Products have been recalled or placed under import detention by the FDA, MDS may place
replacement Shipment Orders with KL and KL shall ship such Products by air shipment when required
in MDS’ sole discretion, and shall continue air shipments until the effects of such recall or
import detention have been completed or ended. To the extent MDS requires substitute products for
recalled or detained Products, such substitutes will be credited on a unit basis toward the
applicable Purchase Commitment and MDS shall submit KL proof of its substitutes from another
supplier. In the event MDS or any of its distributors are prevented from operating as a result of
a recall or FDA action MDS shall be relieved of its Purchase Commitments to the extent such recall
or FDA action prevents the resale of the Products.

     14.3 In the event of such a recall of any of the Products sold by MDS, the parties will
cooperate fully with each other in effecting such recall.

     14.4 In the event that KL or MDS determines that it will recall any Products sold by either of
them because the Products are believed to violate any provision of any law, the guarantees of
Section 9.1 or the warranties provided in Section 10.1, KL or MDS may, once the recall has been
substantially completed, request an arbitrator, appointed by the American Arbitration Association,
who shall determine whether KL’s or MDS’ determination to recall was necessary and reasonable. The
arbitrator may require that KL or MDS bear all costs, damages and expenses of such recall or may
apportion such costs and expenses between the parties as the arbitrator deems just under all of the
circumstances.

 

 

     14.5 MDS shall bear all costs and expenses of a recall or import detention of the Products
caused by the negligence of MDS. KL shall bear all costs and expenses of a recall or import
detention of the Products caused by the negligence of KL.

     14.6 In the event of a recall or FDA action that restricts the supply in the United States of
products similar or functionally equivalent to the Products, KL will use its reasonable efforts to
increase production as may be required to assure a continued source of supply to affected patients
and in this regard MDS shall maintain and keep MDS inventories in accordance with the Purchase
Commitments and forecasts provided in Sections 3.2 and 3.3.

ARTICLE 15

RIGHT OF FIRST REFUSAL

     15.1 During the first [**] months following the Effective Date (the “Exclusive Negotiation
Period”), KL shall have the exclusive and first right to negotiate an agreement with MDS relating
to the sale and/or distribution of MDS’ Streamline BTL in Asia, including, without limitation,
Japan (an “Asian Streamline Distribution Agreement”). During the Exclusive Negotiation Period, MDS
will not enter into discussions or negotiations with any third party regarding an Asian Streamline
Distribution Agreement, without first obtaining the written consent of KL. Following any written
request by KL to commence discussions or negotiations of an Asian Streamline Distribution
Agreement, KL and MDS each agree to discuss and negotiate in good faith and to make their
respective representatives available at reasonable times and with reasonable frequency to conduct
such negotiations, and shall share information relevant to the discussions and negotiations,
consistent with customary business practices of the industry. If KL does not exercise its
negotiation right or if the parties cannot agree on the terms and conditions of an Asian Streamline
Distribution Agreement, then at the end of the Exclusive Negotiation Period, KL’s rights under this
Section 15.1, with respect thereto will terminate.

ARTICLE 16

NOTICES

     16.1 Even if not expressly so provided, all notices required or permitted to be given pursuant
or in reference to this Agreement shall be in writing and shall be given by registered airmail,
with appropriate postage prepaid or in the form of a telefax, followed immediately by a
confirmation letter by registered airmail. Such notice shall be directed to the following
addresses:

If to KL:

Kawasumi Laboratories, Inc.

3-28-15 Minami-Ohi, Shinagawa-ku

Tokyo, 140-8555, Japan

Facsimile: 81-3-3763-2351

Attention: Managing Director, Leader of Business Units

If to MDS:

 

 

Medisystems Corporation

439 South Union Street, 5th Floor

Lawrence, MA, 10843 U.S.A.

Facsimile: 1-978-687-4805

Attention: President with a copy to General Counsel

or to such other address as to which either party may notify the other. Notice given as herein
provided shall be considered to have been given seven (7) days after the mailing thereof, or if
delivered by telefax, when received.

ARTICLE 17

TERMINATION OF 2001 AGREEMENT FOR BTL AND NX

     17.1 KL and MDS agree to terminate the 2001 Agreement in its entirety solely with respect to
BTL and NX as of January 31, 2008, and have this Agreement supersede the terms and conditions of
the 2001 Agreement with respect to the supply and distribution of the BTL and NX between the
parties. For clarification purposes, the 2001 Agreement shall continue to be in full force and
effect with respect to AVF, BH, VN and PHE, and shall govern the supply and distribution thereof
between the parties.

ARTICLE 18

ENTIRE AGREEMENT

     18.1 This Agreement contains the entire agreement between the parties relating to the Products
and Components and all prior proposals, discussions, and writings by and between the parties and
relating to the subject matter herein are superseded by this Agreement, it being expressly
understood that the 2001 Agreement shall remain in full force and effect with respect to AVF, BH,
VN and PHE.

ARTICLE 19

EFFECT OF HEADINGS

     19.1 The headings to Articles and Sections of this Agreement are to facilitate reference only,
and do not form a part of this Agreement and shall not in any way affect or be considered in the
interpretation hereof.

ARTICLE 20

NON-WAIVER AND MODIFICATION

     20.1 None of the terms of this Agreement shall be deemed to be waived by either party nor
amended unless such waiver is in writing and is signed by the party to be charged with such waiver,
or the amendment is in writing and signed by both parties, and such writing recites specifically
that it is a waiver of, or amendment to, the terms of this Agreement.

 

 

ARTICLE 21

ASSIGNMENT

     21.1 Neither this Agreement, nor any rights and obligations hereunder, shall be assigned by
any of the parties hereto to any other person, firm or corporation other than an affiliate, without
the express prior written consent thereto by the other party. This Agreement shall be binding
upon, and inure to the benefit of, the parties, their successors, and permitted assigns.

ARTICLE 22

DISCLAIMER OF AGENCY

     22.1 This Agreement shall not constitute either of the parties hereto the legal representative
or the agent of the other party hereto for any purpose whatsoever, nor shall either party hereto
have any right or authority to assume, create or incur in any manner any obligation or other
liability or any kind or nature, express or implied, against, or in the name or on behalf of, the
other party hereto.

ARTICLE 23

GOVERNING LANGUAGE

     23.1 This Agreement is in the English language only, which language shall be controlling in
all respects.

ARTICLE 24

APPLICABLE LAW

     24.1 The validity, construction and performance of this Agreement shall be governed by and
interpreted in accordance with the laws of the State of New York without giving effect to any
choice of law rule that would cause application of the laws of any other jurisdiction, and in no
event will this Agreement be governed by, and the parties expressly disclaim application of, the
United Nations Convention on Contracts for the International Sale of Goods.

ARTICLE 25

ARBITRATION

     25.1 All disputes arising in connection with this Agreement shall be finally settled under the
Rules of Conciliation and Arbitration of the International Chamber of Commerce by one or more
arbitrators in accordance with the said rules. The arbitration shall take place in Tokyo, Japan if
the dispute is initiated by MDS and in Seattle, Washington, U.S.A., if initiated by KL.

ARTICLE 26

SAVING CLAUSE

     26.1 In the event that any provision or provisions of this Agreement shall be void, unlawful
or unenforceable, such provision or provisions shall be deemed excluded from this

 

 

Agreement, but this Agreement shall not otherwise be affected thereby and the remaining
provisions hereof shall continue in full force and effect.

ARTICLE 27

GLOSSARY OF DEFINED TERMS USED IN THIS AGREEMENT

     Following are the definitions of terms used in and for the purposes of this Agreement.

     27.1 “2001 Agreement” has the meaning set forth in Section 1.4.

     27.2 “Act” means the United States Federal Food, Drug and Cosmetic Act, as amended from time
to time.

     27.3 “Agreement” has the meaning set forth in the Preamble.

     27.4 “Asian Streamline Distribution Agreement” has the meaning set forth in Section 15.1.

     27.5 “AVF” means [**] and larger needle sets, such as AV fistula needle sets used in
artificial kidney dialysis procedures.

     27.6 “Baht/US$Exchange Rate” has the meaning set forth in Section 5.3.

     27.7 “Base PVC Price” has the meaning set forth in Section 5.4.

     27.8 “BH” means buttonhole needles.

     27.9 “BTL” means blood tubing line sets used in artificial kidney dialysis and other similar
extracorporeal procedures.

     27.10 “Codes” means the individual product codes used to identify each product model.

     27.11 “Components” means, collectively, the parts, components, and other materials designed by
MDS to be used in the Products which are listed in Annex A, which may be revised from time to time
pursuant to Section 2.1.

     27.12 “Component Order” means the firm shipment order for the Components.

     27.13 “Component Order Date” has the meaning set forth in Section 3.3d.

     27.14 “Contract Year” means the twelve-month period following the Effective Date and each
subsequent twelve-month period during the Term.

     27.15 “Current PVC Price” has the meaning set forth in Section 5.4.

     27.16 “[**]” means [**].

     27.17 “Dead Stock” means components with a limited useful life that are not incorporated into
sold Products in a timely fashion.

 

 

     27.18 “Effective Date” means February 1, 2008.

     27.19 “Exclusive Negotiation Period” has the meaning set forth in Section 15.1.

     27.20 “FDA” means the United States Food and Drug Administration.

     27.21 “Final KL Forecast” has the meaning set forth in Section 3.3c.3.

     27.22 “Final MDS Forecast” has the meaning set forth in Section 3.3a.3.

     27.23 “First KL Forecast” has the meaning set forth in Section 3.3c.1.

     27.24 “First MDS Forecast” has the meaning set forth in Section 3.3a.1.

     27.25 “Following Renewal Term” has the meaning set forth in Section 3.2i.

     27.26 “Freight Costs” has the meaning set forth in Section 5.2.

     27.27 “Forecast Date” has the meaning set forth in Section 3.3a.

     27.28 “Initial Goal” has the meaning set forth in Section 3.2a.

     27.29 “Initial Maximum Order Quantity” has the meaning set forth in Section 3.2j.

     27.30 “Initial Purchase Commitment” has the meaning set forth in Section 3.2a.

     27.31 “Initial Shortfall” has the meaning set forth in Section 3.2b.

     27.32 “Initial Shortfall Shipments” has the meaning set forth in Section 3.2b.

     27.33 “Initial Streamline Purchase Commitment” has the meaning set forth in Section 3.2c.

     27.34 “Initial Term” has the meaning set forth in Section 11.1.

     27.35 “KL” means Kawasumi Laboratories, Inc., Kawasumi Laboratories America, Inc., Kawasumi
Laboratories Europe GMBH, and Kawasumi Laboratories (Thailand) Co., Ltd., collectively.

     27.36 “Locations” has the meaning set forth in Section 3.4.

     27.37 “Maximum Exchange Rate” has the meaning set forth in Section 5.3.

     27.38 “Minimum Exchange Rate” has the meaning set forth in Section 5.3.

     27.39 “MDS” means Medisystems Corporation, Medisystems Europe. Srl., and Medimexico S. de R.L.
de C.V., collectively.

 

 

     27.40 “NX” means tubing and/or bag sets suitable for use with NxStage Medical, Inc. renal
therapy equipment.

     27.41 “PHE” means [**] and larger needle sets, such as pheresis needles including unsterile
sub-assemblies for pheresis and other similar extracorporeal blood therapies.

     27.42 “Product Prices” has the meaning set forth in Section 5.2.

     27.43 “Products” means, collectively, BTL and NX products which Codes are listed in Annex A,
which may be revised from time to time pursuant to Section 2.1.

     27.44 “Purchase Commitment(s)” means, collectively, the Initial Purchase Commitment, the
Initial Streamline Purchase Commitment, and all Renewal Purchase Commitments.

     27.45 “PVC Cost Ratio” has the meaning set forth in Section 5.4.

     27.46 “PVC Price” has the meaning set forth in Section 5.4.

     27.47 “PVC Price Decrease Ratio” has the meaning set forth in Section 5.4.

     27.48 “PVC Price Increase Ratio” has the meaning set forth in Section 5.4.

     27.49 “QA Agreement” means the Quality Assurance Agreement, dated as of October 25, 1999,
between MDS and KL.

     27.50 “Renewal Goal” has the meaning set forth in Section 3.2g.

     27.51 “Renewal Maximum Order Quantity” has the meaning set forth in Section 3.2k.

     27.52 “Renewal Purchase Commitment” has the meaning set forth in Section 3.2g.

     27.53 “Renewal Shortfall” has the meaning set forth in Section 3.2h.

     27.54 “Renewal Shortfall Shipments” has the meaning set forth in Section 3.2h.

     27.55 “Renewal Term” has the meaning set forth in Section 11.1.

     27.56 “Revised Initial Commitment Term” has the meaning set forth in Section 3.2f.

     27.57 “Shipment Order” means the firm shipment order for the Products.

     27.58 “Shipment Order Date” has the meaning set forth in Section 3.3b.

     27.59 “Shipment Period” has the meaning set forth in Section 3.3b.

     27.60 “Specifications” means the specifications set forth in the QA Agreement.

     27.61 “Streamline BTL” means the BTL products designated as streamline BTL products in Annex
A.

 

 

     27.62 “Supply Commitment” has the meaning set forth in Section 3.2l.

     27.63 “Term” has the meaning set forth in Section 11.1.

     27.64 “Territory” means the different geographical area(s) for sale, resale or use for
different Products described in Annex B.

     27.65 “VN” means sets suitable for subcutaneous access devices such as the VascA, Inc.
LifeSite blood access valve.

 

 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be signed by their authorized
representatives as of the date set forth in the preamble.

KAWASUMI LABORATORIES, INC.

/s/
Yukihiro
Kawano 

Yukihiro Kawano

President

MEDISYSTEMS CORPORATION

/s/ Jeffrey H. Burbank 

Jeffrey H. Burbank

Presidentexv4w2

Exhibit 4.2

REGISTRATION RIGHTS AGREEMENT

by and among

Sun-Times Media Group, Inc.

and the STOCKHOLDERS named herein

 

Dated: June 17, 2008

 

 

REGISTRATION RIGHTS AGREEMENT

          REGISTRATION RIGHTS AGREEMENT, dated as of June 17, 2008, by and among Sun-Times Media Group,
Inc. (the “Company”), Hollinger Inc., 4322525 Canada Inc. and the stockholders that are
party to this Agreement from time to time, as set forth on the signature page hereto.

          WHEREAS, the parties hereto desire to provide for, among other things, the grant of
registration rights with respect to the Registrable Securities (as hereinafter defined).

          NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein and
for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the
parties hereto agree as follows:

          1. (a) Definitions. As used in this Agreement, and unless the context requires a
different meaning, the following terms have the meanings indicated:

          “Affiliate” means, with respect to a Person, any other Person directly or indirectly
controlling or controlled by or under direct or indirect common control with such specified Person.
For purposes of this definition, “control” (including, with correlative meanings, the terms
“controlling,” “controlled by” and “under common control with”), as used with respect to a Person,
shall mean the possession, directly or indirectly, of the power to direct or cause the direction of
the management or policies of such Person, whether through the ownership of voting securities, by
agreement or otherwise.

          “Agreement” means this Registration Rights Agreement as the same may be amended,
supplemented or modified in accordance with the terms hereof.

          “Approved Underwriter” has the meaning set forth in Section 3(f) of this Agreement.

          “Automatic Shelf Registration Statement” means an “automatic shelf registration
statement” as defined in Rule 405 promulgated under the Securities Act that becomes effective upon
filing thereof pursuant to General Instructions I.D. of Form S-3.

          “Board of Directors” means the Board of Directors of the Company.

          “Business Day” means any day other than a Saturday, Sunday or other day on which
commercial banks in the State of New York or Illinois are authorized or required by law or
executive order to remain closed.

          “Commission” means the Securities and Exchange Commission or any similar agency then
having jurisdiction to enforce the Securities Act.

          “Common Stock” means (i) the Class A Common Stock, par value $0.001 per share, of the
Company, (ii) any other common stock of the Company, (iii) any

 

securities of the Company or any successor or assign of the Company into which such stock
described in clauses (i) and (ii) is reclassified or reconstituted or into which such stock is
converted or otherwise exchanged in connection with a combination of shares, recapitalization,
merger, sale of assets, consolidation or other reorganization or otherwise or (iv) any securities
received as a dividend or distribution in respect of the securities described in clauses (i), (ii),
and (iii) above.

          “Company” has the meaning set forth in the preamble to this Agreement.

          “Company Underwriter” has the meaning set forth in Section 4(a) of this Agreement.

          “Demand Registration” has the meaning set forth in Section 3(a) of this Agreement.

          “Designated Stockholder” means Hollinger Inc., 4322525 Canada Inc., and the assignees
of each of the foregoing as permitted by Section 2(d) of this Agreement.

          “Designated Stockholders’ Counsel” has the meaning set forth in Section 8(a)(i) of
this Agreement.

          “Disclosure Package” means, with respect to any offering of securities, (i) the
preliminary Prospectus, (ii) each Free Writing Prospectus and (iii) all other information, in each
case, that is deemed, under Rule 159 promulgated under the Securities Act, to have been conveyed to
purchasers of securities at the time of sale of such securities (including, without limitation, a
contract of sale).

          “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules
and regulations of the Commission thereunder.

          “FINRA” means the Financial Industry Regulatory Authority or any successor agency
thereto.

          “Free Writing Prospectus” means any “free writing prospectus” as defined in Rule 405
promulgated under the Securities Act.

          “Hedging Counterparty” means a broker-dealer registered under Section 15(b) of the
Exchange Act or an Affiliate thereof.

          “Hedging Transaction” means any transaction involving a security linked to the
Registrable Securities or any security that would be deemed to be a “derivative security” (as
defined in Rule 16a-1(c) promulgated under the Exchange Act) with respect to the Registrable
Securities or transaction (even if not a security) which would (were it a security) be considered
such a derivative security, or which transfers some or all of the economic risk of ownership of the
Registrable Securities, including, without limitation, any forward contract, equity swap, put or
call, put or call equivalent position, collar, non-recourse loan, sale of exchangeable security or
similar transaction. For the avoidance of doubt, the following transactions shall be deemed to be
Hedging Transactions:

2

 

          (a) transactions by a Designated Stockholder in which a Hedging Counterparty engages in short
sales of Registrable Securities pursuant to a Prospectus and may use Registrable Securities to
close out its short position;

          (b) transactions pursuant to which a Designated Stockholder sells short Registrable Securities
pursuant to a Prospectus and delivers Registrable Securities to close out its short position; and

          (c) transactions by a Designated Stockholder in which the Designated Stockholder delivers, in
a transaction exempt from registration under the Securities Act, Registrable Securities to the
Hedging Counterparty who will then publicly resell or otherwise transfer such Registrable
Securities pursuant to a Prospectus or an exemption from registration under the Securities Act.

          “Incidental Registration” has the meaning set forth in Section 4(a) of this Agreement.

          “Indemnified Party” has the meaning set forth in Section 9(c) of this Agreement.

          “Indemnifying Party” has the meaning set forth in Section 9(c) of this Agreement.

          “Indentures” means (a) the indenture of Hollinger Inc., dated as of March 10, 2003 (as
amended), pursuant to which Delaware Trust Company, National Association acts as trustee and (b)
the indenture of Hollinger Inc., dated as of September 30, 2004, pursuant to which HSBC Bank USA,
National Association acts as trustee.

          “Indenture Trustees” means Delaware Trust Company, National Association and HSBC Bank
USA, National Association, in their respective capacities as trustees under the Indentures and
collateral agents under the related agreements, and their successors.

          “Initiating Holders” means the 25% Designated Stockholders.

          “Inspector” has the meaning set forth in Section 8(a)(viii) of this Agreement.

          “Liability” has the meaning set forth in Section 9(a) of this Agreement.

          “Majority Initiating Holders” means Initiating Holders holding at least a majority of
the Registrable Securities held by all of the Initiating Holders.

          “Majority S-3 Initiating Holders” means S-3 Initiating Holders holding at least a
majority of the Registrable Securities held by all of the S-3 Initiating Holders.

          “Permitted Assignee” means, with respect to any Person, to the extent applicable,
(i) such Person’s parents, spouse, siblings, children (including stepchildren

3

 

and adopted children), children’s spouses, grandchildren or grandchildren’s spouses thereof
(“Family Members”), (ii) a corporation, partnership or limited liability company, a
majority of the beneficial interests of which shall be held by such Person, such Person’s
Affiliates and/or such Person’s Family Members, (iii) a trust, the beneficiaries of which are such
Person and/or such Person’s Family Members, (iv) such Person’s heirs, executors, administrators,
estate or a trust under such Person’s will, (v) an entity described in Section 501(c)(3) of the
United States Internal Revenue Code of 1986, as amended, that is established by such Person,
(vi) any Affiliate of such Person, (vii) any Person to whom such Person has pledged the Registrable
Securities as collateral to secure outstanding indebtedness or (viii) any other transferee to whom
such Person transfers Registrable Securities if upon such transfer, such transferee would
beneficially own 5% or more of the outstanding Common Stock.

          “Permitted Withdrawal” has the meaning set forth in Section 3(g) of this Agreement.

          “Person” means any individual, firm, corporation, partnership, limited liability
company, trust, incorporated or unincorporated association, joint venture, joint stock company,
limited liability company, government (or an agency or political subdivision thereof) or other
entity of any kind, and shall include any successor (by merger or otherwise) of such entity.

          “Pledgee” has the meaning set forth in Section 2(d)(i).

          “Prospectus” means the prospectus related to any Registration Statement (including,
without limitation, a prospectus or prospectus supplement that discloses information previously
omitted from a prospectus filed as part of an effective registration statement in reliance on Rule
415, 430A or 430B (or any successor rules or regulations) under the Securities Act), as amended or
supplemented by any amendment or prospectus supplement, including post-effective amendments, and
all materials incorporated by reference in such prospectus.

          “Records” has the meaning set forth in Section 8(a)(viii) of this Agreement.

          “Registrable Securities” means, subject to Section 2(b) and Section 2(d)(i), any and
all shares of Common Stock issued to Designated Stockholders upon conversion of the Company’s Class
B Common Stock or as “Additional Shares” pursuant to the Settlement.

          “Registration Expenses” has the meaning set forth in Section 8(d) of this Agreement.

          “Registration Statement” means a registration statement filed pursuant to the
Securities Act.

          “S-3 Initiating Holders” has the meaning set forth in Section 5(a) of this Agreement.

4

 

          “S-3 Participating Stockholders” has the meaning set forth in Section 5(a) of this
Agreement.

          “S-3 Registration” has the meaning set forth in Section 5(a) of this Agreement.

          “Seasoned Issuer” means an issuer eligible to use Form S-3 or F-3 for a primary
offering in reliance on General Instruction I.B.1 to those Forms.

          “Securities Act” means the Securities Act of 1933, as amended, and the rules and
regulations of the Commission promulgated thereunder.

          “Settlement” means that certain Multi-Party Settlement Term Sheet, dated May 14, 2008,
and approved by the Ontario Superior Court of Justice (Commercial List) in an Order (Approval of
Multi-Party Settlement and Cost Reduction/Asset Enhancement Program) entered May 27, 2008.

          “underwritten offering” of securities means a public offering of such securities
registered under the Securities Act in which an underwriter, placement agent or other intermediary
participates in the distribution of such securities, including, without limitation, a Hedging
Transaction in which a Hedging Counterparty participates.

          “Valid Business Reason” has the meaning set forth in Section 3(a) of this Agreement.

          “Well-Known Seasoned Issuer” means a “well-known seasoned issuer” as defined in
Rule 405 of the General Rules and Regulations promulgated under the Securities Act and which (a) is
a “well-known seasoned issuer” under paragraph (1)(i)(A) of such definition or (b) is a “well-known
seasoned issuer” under paragraph (1)(i)(B) of such definition and is also eligible to register a
primary offering of its securities relying on General Instruction I.B.1 of Form S-3 or Form F-3
under the Securities Act.

          “25% Designated Stockholders” means the Designated Stockholders holding more than
twenty-five percent (25%) of the Registrable Securities held by all Designated Stockholders.

               (b) Interpretation. Unless otherwise noted:

                    (i) All references to laws, rules, regulations and forms in this Agreement shall be deemed to
be references to such laws, rules, regulations and forms, as amended from time to time or, to the
extent replaced, the comparable successor thereto in effect at the time.

                    (ii) All references to agencies, self-regulatory organizations or governmental entities in
this Agreement shall be deemed to be references to the comparable successor thereto.

5

 

                    (iii) All references to agreements and other contractual instruments shall be deemed to be
references to such agreements or other instruments as they may be amended from time to time.

          2. General; Securities Subject to this Agreement.

               (a) Grant of Rights. The Company hereby grants registration rights to the Designated
Stockholders upon the terms and conditions set forth in this Agreement.

               (b) Registrable Securities. For the purposes of this Agreement, Registrable
Securities held by any Designated Stockholder will cease to be Registrable Securities, when (i) a
Registration Statement covering such Registrable Securities has been declared effective under the
Securities Act by the Commission and such Registrable Securities have been disposed of pursuant to
such effective Registration Statement, (ii) the entire amount of the Registrable Securities held by
any Designated Stockholder may be sold in a single sale, in the opinion of counsel reasonably
satisfactory to the Company and such Designated Stockholder (which may be counsel to the Company or
the Designated Stockholder), without any limitation as to volume pursuant to Rule 144 (or any
successor rule or regulation) under the Securities Act or (iii) the Registrable Securities have
ceased to be outstanding.

               (c) Holders of Registrable Securities. A Person is deemed to be a holder of
Registrable Securities whenever such Person owns of record Registrable Securities. If the Company
receives conflicting instructions, notices or elections from two or more Persons with respect to
the same Registrable Securities, the Company may act upon the basis of the instructions, notice or
election received from the registered owner of such Registrable Securities.

               (d) Transfer of Registration Rights.

                    (i) Each Designated Stockholder may transfer or pledge Registrable Securities with the
associated registration rights under this Agreement (including transfers occurring by operation of
law or by reason of intestacy) to a Permitted Assignee or a pledgee (“Pledgee”) only if
(1) such Permitted Assignee or Pledgee agrees in writing to be bound as a Designated Stockholder by
the provisions of this Agreement, with such agreement substantially in the form of Annex A
hereto, and (2) immediately following such transfer or pledge, the further disposition of such
Registrable Securities by such Permitted Assignee or Pledgee would be restricted under the
Securities Act and the entire amount of all such Registrable Securities could not be sold in a
single sale, in the opinion of counsel reasonably satisfactory to the Company and such Designated
Stockholder (which may be counsel to the Company or the Designated Stockholder), without any
limitation as to volume pursuant to Rule 144 (or any successor rule or regulation) under the
Securities Act; provided that (A) the parties expressly acknowledge that the initial
Designated Stockholders have pledged the Exchanged Shares and the Additional Shares (as each such
term is defined in the Settlement) in favor of the Indenture Trustees in accordance with the terms
of the corresponding Indentures and

6

 

related agreements, and that the Indenture Trustees are Pledgees for purposes of this
Agreement, and (B) neither Indenture Trustee shall be required to execute the agreement in the form
of Annex A hereto until the date(s) either such Indenture Trustee shall determine in
connection with the exercise of such Indenture Trustee’s rights and powers under the Indentures and
related agreements. Upon any transfer of Registrable Securities other than as set forth in this
Section 2(d), such securities shall no longer constitute Registrable Securities.

                       (ii) If a Designated Stockholder assigns its rights under this Agreement in connection with
the transfer of less than all of its Registrable Securities, the Designated Stockholder shall
retain its rights under this Agreement with respect to its remaining Registrable Securities. If a
Designated Stockholder assigns its rights under this Agreement in connection with the transfer of
all of its Registrable Securities, such Designated Stockholder shall have no further rights or
obligations under this Agreement, except under Section 8 hereof in respect of offerings in which it
participated.

          3. Demand Registration.

               (a) Request for Demand Registration. At any time, and from time to time, the
Initiating Holders may make a written request to the Company to register, and the Company shall
register, under the Securities Act, in accordance with the terms of this Agreement (a “Demand
Registration”), the number of Registrable Securities stated in such request; provided, however,
that the Company shall not be obligated to effect (i) more than two such Demand Registrations or
(ii) any such Demand Registration within ninety (90) days after the effective date of any other
Registration Statement of the Company (other than a Registration Statement on Form S-4 or S-8 or
any successor form thereto). For purposes of this Section 3(a), two (2) or more Registration
Statements filed in response to one (1) demand shall be counted as one (1) Demand Registration. In
addition, if the Company’s Board of Directors determine in good faith that any registration of
Registrable Securities should not be made or continued because it would materially and adversely
affect any material financing, acquisition, corporate reorganization or merger or other material
transaction involving the Company or would involve initial or continuing disclosure obligations
that would not be in the best interests of the Company (a “Valid Business Reason”), (x) the
Company may postpone filing a Registration Statement (but not the preparation of the Registration
Statement) relating to a Demand Registration until such Valid Business Reason no longer exists and
(y) in case a Registration Statement has been filed relating to a Demand Registration, the Company
may postpone amending or supplementing such Registration Statement until such Valid Business Reason
no longer exists; provided, however, that in no event shall the postponement of the
filing of any Registration Statement or the postponement of the amending or supplementing of any
previously filed Registration Statement exceed an aggregate of 180 days in any 365-day period;
provided, further, that if any single postponement shall extend beyond ninety (90)
consecutive days, the Board of Directors of the Company shall make a confirmatory determination
that a Valid Business Reason continues to exist on or prior to such ninetieth (90th) day. The
Company shall give written notice to all Designated Stockholders of its determination to postpone
the filing of

7

 

a Registration Statement or to postpone the amending or supplementing thereof and of the fact
that the Valid Business Reason for such postponement no longer exists, in each case, promptly after
the occurrence thereof. Each request for a Demand Registration by the Initiating Holders shall
state the amount of the Registrable Securities proposed to be sold and the intended method of
disposition thereof.

               (b) Incidental or “Piggy-Back” Rights with Respect to a Demand Registration. Any
Designated Stockholder which has not requested a registration under Section 3(a) may, pursuant to
this Section 3(b), offer its Registrable Securities under any Demand Registration. The Company
shall (i) as promptly as practicable, but in no event later than five (5) days after the receipt of
a request for a Demand Registration from the Initiating Holders, give written notice thereof to all
of the Designated Stockholders (other than Initiating Holders which have requested a registration
under Section 3(a)), which notice shall specify the number of Registrable Securities subject to the
request for Demand Registration, the names and notice information of the Initiating Holders and the
intended method of disposition of such Registrable Securities, and (ii) subject to Section 3(e),
include in the Registration Statement filed pursuant to the Demand Registration all of the
Registrable Securities held by such Designated Stockholders from whom the Company has received a
written request for inclusion therein within ten (10) days of the date on which the Company sent
the written notice referred to in clause (i) above. Each such request by such Designated
Stockholders shall specify the number of Registrable Securities proposed to be registered. The
failure of any Designated Stockholder to respond within such 10-day period referred to in clause
(ii) above shall be deemed to be a waiver of such Designated Stockholder’s rights under this
Section 3(b) with respect to such Demand Registration. Any Designated Stockholder may waive its
rights under this Section 3(b) prior to the expiration of such 10-day period by giving written
notice to the Company.

               (c) Effective Demand Registration. Subject to Section 3(a), the Company shall use its
commercially reasonable efforts to cause any such Demand Registration to become effective as
promptly as practicable but in no event later than the later of (i) one hundred and twenty (120)
days after it receives a request under Section 3(a) hereof and (ii) ninety (90) days after the
effective date of any other Registration Statement of the Company (other than a Registration
Statement on Form S-4 or S-8 or any successor form thereto) that had been filed but not yet
declared effective at the time such Demand Registration was made, and to remain continuously
effective for the lesser of (i) the period during which all Registrable Securities registered in
the Demand Registration are sold or (ii) two hundred and seventy (270) days following the date on
which the Registration Statement is declared effective; provided in the case of clause (ii) that
such period shall be extended by the total number of days that such period is interrupted by a
postponement pursuant to Section 3(a)). A registration shall not constitute a Demand Registration
if (x) after such Demand Registration has become effective, such registration or the related offer,
sale or distribution of Registrable Securities thereunder is interfered with by any stop order,
injunction or other order or requirement of the Commission or other governmental agency or court
for any reason not attributable to the Initiating Holders and such interference is not thereafter
eliminated, or (y) the conditions specified in the underwriting agreement, if any, entered into in

8

 

connection with such Demand Registration are not satisfied or waived, other than by reason of
a failure by the Initiating Holders.

               (d) Expenses. Except as provided in Section 3(g) and 8(d), the Company shall pay all
Registration Expenses in connection with a Demand Registration, whether or not such Demand
Registration becomes effective.

               (e) Underwriting Procedures. If the Company or the Majority Initiating Holders so
elect, the Company shall use its commercially reasonable efforts to cause the offering made
pursuant to such Demand Registration to be in the form of a firm commitment underwritten offering
and the managing underwriter or underwriters selected for such offering shall be the Approved
Underwriter selected in accordance with Section 3(f). In connection with any Demand Registration
under this Section 3 involving an underwritten offering, none of the Registrable Securities held by
any Designated Stockholder making a request for inclusion of such Registrable Securities pursuant
to Section 3(a) or 3(b) hereof shall be included in such underwritten offering unless such
Designated Stockholder accepts the terms of the offering as agreed upon by the Company, the
Majority Initiating Holders and the Approved Underwriter, and then only in such quantity as set
forth in this Section 3(e). If the Approved Underwriter advises the Company that the aggregate
amount of such Registrable Securities requested to be included in such offering is sufficiently
large to have a material adverse effect on the distribution of sales price of the Registrable
Securities in such offering, then the Company shall include in such Demand Registration, to the
extent of the amount that the Approved Underwriter believes may be sold without causing such
material adverse effect, (i) first, such number of Registrable Securities of the Designated
Stockholders participating in the offering under Section 3(a) or 3(b), which Registrable Securities
shall be allocated pro rata among such Designated Stockholders participating in the offering, based
on the number of Registrable Securities held by each such Designated Stockholder, (ii)
second, if all of the Registrable Securities referenced in clause (i) have been included,
any other securities of the Company requested by holders thereof to be included in such
registration, pro rata among such other holders on the basis of the number of securities that each
such holder requested to be included in such registration, except to the extent any such holders
have agreed to grant priority with regard to participation in such registration to any of the other
holders, and (iii) third, if all of the Registrable Securities referenced in clause (i) and
(ii) have been included, any securities offered by the Company for its own account.

               (f) Selection of Underwriters. If any Demand Registration or S-3 Registration, as the
case may be, of Registrable Securities is in the form of an underwritten offering, the Company
shall select and obtain one or more investment banking firms of national reputation to act as the
managing underwriter or underwriters of the offering; provided, however, that such
firm shall, in any case, also be approved by the Majority Initiating Holders or Majority S-3
Initiating Holders, as the case may be, such approval not to be unreasonably delayed or withheld.
Notwithstanding the foregoing, if any S-3 Registration of Registrable Securities is in the form of
a Hedging Transaction, the Majority S-3 Initiating Holders shall select and obtain an investment
banking firm of national reputation to act as the managing underwriter (or the equivalent

9

 

position) of the Hedging Transaction; provided, however, that such firm shall,
in any case, also be approved by the Company, such approval not to be unreasonably delayed or
withheld. An investment banking firm or firms selected pursuant to this Section 3(f) shall be
referred to as the “Approved Underwriter” in this Agreement.

               (g) Withdrawal. The Majority Initiating Holders shall be entitled to withdraw or
revoke a request for a Demand Registration without the prior written consent of the Company if (i)
such withdrawal or revocation is as a result of facts or circumstances arising after the date on
which a request for a Demand Registration was made and the Initiating Holders reasonably determine
that participation in such registration would have a material adverse effect on the Initiating
Holders or (ii) the Initiating Holders agree to pay all fees and expenses incurred by the Company
in connection with such withdrawn registration (each, a “Permitted Withdrawal”). If a
Permitted Withdrawal occurs under clauses (i) above, the related Demand Registration shall be
counted as a Demand Registration for purposes of Section 3(a), and if a Permitted Withdrawal occurs
under clause (ii) above, the related Demand Registration shall not be counted as a Demand
Registration for purposes of Section 3(a). Any Permitted Withdrawal shall constitute and effect an
automatic withdrawal by all other Initiating Holders and any other Designated Stockholder
participating in such Demand Registration pursuant to the provisions of Section 3(b).

          4. Incidental or “Piggy-Back” Registration.

               (a) Request for Incidental or “Piggy-Back” Registration. At any time and from time to
time, if the Company proposes to file a Registration Statement with respect to an offering of
Common Stock by the Company for its own account (other than a Registration Statement on Form S-4 or
S-8 or any successor form thereto) or for the account of any stockholder of the Company other than
Designated Stockholders pursuant to Sections 3 and 5 hereof, then the Company shall give written
notice of such proposed filing to each of the Designated Stockholders at least twenty (20) days
before the anticipated filing date, which notice shall describe the proposed registration and
distribution and offer such Designated Stockholders the opportunity to register the number of
Registrable Securities that each such Designated Stockholder may request (an “Incidental
Registration”). The Company shall use its commercially reasonable efforts (within twenty (20)
days after the notice provided for in the preceding sentence) to cause the managing underwriter or
underwriters in the case of a proposed underwritten offering (the “Company Underwriter”) to
permit each Designated Stockholder who has requested in writing to participate in the Incidental
Registration pursuant to this Section 4(a) to include the number of such Designated Stockholder’s
Registrable Securities indicated by such Designated Stockholder in such offering on the same terms
and conditions as the Common Stock of the Company or the account of such other stockholder, as the
case may be, included therein. Prior to the effective date of the Registration Statement with
respect to which such Incidental Registration has been requested, immediately upon determination of
the price at which such Registrable Securities are to be sold, if such price is below the price
which any Designated Stockholder who requested to participate in the Incidental Registration finds
acceptable, such Designated Stockholder shall then have the right, by written notice to the
Company, to withdraw its request to have its

10

 

Registrable Securities included in such Registration Statement. Any withdrawal of the
Registration Statement by the Company for any reason shall constitute and effect an automatic
withdrawal of any Incidental Registration with respect to such Designated Stockholder so
withdrawing. In connection with any Incidental Registration under this Section 4(a) involving an
underwritten offering, the Company shall not be required to include any Registrable Securities in
such underwritten offering unless the Designated Stockholders thereof accept the terms of the
underwritten offering as agreed upon between the Company, such other stockholders, if any, and the
Company Underwriter, and then only in such quantity as set forth below in this Section 4(a). If
the Company Underwriter determines that the registration of all or part of the securities that have
been requested to be included would materially adversely affect the distribution or sales price of
the securities in such offering, then the Company shall be required to include in such Incidental
Registration, to the extent of the amount that the Company Underwriter believes may be sold without
causing such material adverse effect, (i) first, all of the shares of Common Stock to be
offered for the account of the Company, in the case of a Company initiated Incidental Registration,
or the stockholders who have requested such Incidental Registration, in the case of a stockholder
initiated Incidental Registration, (ii) second, if all of the Registrable Securities
referenced in clause (i) have been included, any Registrable Securities and any other shares of
Common Stock requested by holders thereof (including the Designated Stockholders) to be included in
such registration, pro rata among the Designated Stockholders and such other holders on the basis
of the number of securities that each such holder requested to be included in such Incidental
Registration, except to the extent any such other holders have agreed to grant priority with regard
to participation in such registration to any of the other holders, and (iii) third, if all
of the Registrable Securities referenced in clause (i) and (ii) have been included, all of the
shares of Common Stock to be offered for the account of the Company, in the case of a stockholder
initiated Incidental Registration.

               (b) Expenses. Except as provided in Section 8(d), the Company shall bear all
Registration Expenses in connection with any Incidental Registration pursuant to this Section 4,
whether or not such Incidental Registration becomes effective.

          5. Form S-3 Registration.

               (a) Request for a Form S-3 Registration. Upon the Company becoming eligible for use
of Form S-3 or any successor form thereto under the Securities Act in connection with a secondary
public offering of its equity securities, in lieu of a Demand Registration, in the event that the
Company shall receive from the 25% Designated Stockholders (collectively, the “S-3 Initiating
Holders”) a written request that the Company register under the Securities Act on Form S-3 or
any successor form then in effect (an “S-3 Registration”) the sale of all or a portion of
the Registrable Securities owned by such S-3 Initiating Holders (which S-3 Registration may be a
shelf registration pursuant to Rule 415 promulgated under the Securities Act (or any successor rule
or regulation)), the Company shall give written notice of such request to all of the other
Designated Stockholders (other than S-3 Initiating Holders which have requested an S-3 Registration
under this Section 5(a)) as promptly as practicable but in no event later than

11

 

ten (10) days before the anticipated filing date of such Form S-3, which notice shall describe
the proposed registration, the intended method of disposition of such Registrable Securities and
any other information that at the time would be appropriate to include in such notice, and offer
such other Designated Stockholders the opportunity to register the number of Registrable Securities
as each such Designated Stockholder may request in writing to the Company, given within ten (10)
days of the date on which the Company sent the written notice of such registration. Each request
for an S-3 Registration by the S-3 Initiating Holders shall state the amount of the Registrable
Securities proposed to be sold and the intended method of disposition thereof. With respect to
each S-3 Registration, the Company shall, subject to Section 5(b), (i) include in such offering the
Registrable Securities of the S-3 Initiating Holders and the Designated Stockholders who have
requested in writing to participate in such registration on the same terms and conditions as the
Registrable Securities of the S-3 Initiating Holders included therein (collectively, the “S-3
Participating Stockholders”) and (ii) use its commercially reasonable efforts to cause such
registration pursuant to this Section 5(a) to become and remain effective as soon as practicable,
but in no event later than ninety (90) days after it receives a request therefor and not earlier
than 90 days after the effective date of any other Registration Statement of the Company (other
than a Registration Statement on Form S-4 or S-8 or any successor form thereto) that had been filed
with the Commission but not yet declared effective at the time such registration was requested.
Notwithstanding the foregoing, immediately upon determination of the price at which such
Registrable Securities are to be sold in a S-3 Registration that is a firm commitment underwritten
offering, if such price is below the price which any S-3 Participating Stockholder finds
acceptable, such S-3 Participating Stockholder shall then have the right, by written notice to the
Company, to withdraw its Registrable Securities from being included in such offering; provided,
that such a withdrawal by the Majority S-3 Initiating Holders shall constitute and effect an
automatic withdrawal by all other S-3 Participating Stockholders. If the Majority S-3 Initiating
Holders request, and if the Company is a Well-Known Seasoned Issuer, the Company shall cause such
S-3 Registration to be made pursuant to an Automatic Shelf Registration Statement and may omit the
names of the S-3 Participating Stockholders and the amount of the Registrable Securities to be
offered thereunder.

               (b) Form S-3 Underwriting Procedures. If the Majority S-3 Initiating Holders so
elect, the Company shall use its commercially reasonable efforts to cause such S-3 Registration
pursuant to this Section 5 to be in the form of a firm commitment underwritten offering and the
managing underwriter or underwriters selected for such offering shall be the Approved Underwriter
selected in accordance with Section 3(f). In connection with any S-3 Registration under
Section 5(a) involving an underwritten offering, the Company shall not be required to include any
Registrable Securities in such underwritten offering unless the Designated Stockholders thereof
accept the terms of the underwritten offering as agreed upon between the Company, the Approved
Underwriter and the Majority S-3 Initiating Holders, and then only in such quantity as set forth in
this Section 4(b). If the Approved Underwriter advises the Company that the registration of all or
part of the Registrable Securities which the S-3 Initiating Holders and the other Designated
Stockholders have requested to be included would materially adversely affect the distribution or
sales price of the Registrable

12

 

Securities in such public offering, then the Company shall include in such underwritten
offering, to the extent of the amount that the Approved Underwriter believes may be sold without
causing such material adverse effect, (i) first, such number of Registrable Securities of
the Designated Stockholders participating in the offering under Section 5(a), which Registrable
Securities shall be allocated pro rata among such Designated Stockholders participating in the
offering, based on the number of Registrable Securities held by each such Designated Stockholder,
(ii) second, if all of the Registrable Securities referenced in clause (i) above have been
included, any other securities of the Company requested by holders thereof to be included in such
registration, pro rata among such other holders on the basis of the number of securities that each
such holder requested to be included in such registration, except to the extent any such holders
have agreed under the Existing Agreement to grant priority with regard to participation in such
registration to any of the other holders, and (iii) third, if all of the Registrable
Securities in clause (i) and (ii) have been included, securities offered by the Company for its own
account.

               (c) Limitations on Form S-3 Registrations. If the Board of Directors of the Company
determines in good faith that a Valid Business Reason exists, (x) the Company may postpone filing a
Registration Statement relating to an S-3 Registration (but not the preparation of the Registration
Statement) until such Valid Business Reason no longer exists and (y) in case a Registration
Statement has been filed relating to a S-3 Registration, the Company may postpone amending or
supplementing such Registration Statement until such Valid Business Reason no longer exists;
provided, however, that in no event shall the postponement of the filing of any
Registration Statement relating to an S-3 Registration or the postponement of the amending or
supplementing of any previously filed Registration Statement relating to an S-3 Registration exceed
an aggregate of 180 days in any 365-day period; provided, further, that if any
single postponement shall extend beyond ninety (90) consecutive days, the Board of Directors of the
Company shall make a confirmatory determination that a Valid Business Reason continues to exist on
or prior to such ninetieth (90th) day. The Company shall give written notice to all Designated
Stockholders of its determination to postpone the filing of a Registration Statement relating to an
S-3 Registration or to postpone the amending or supplementing thereof and of the fact that the
Valid Business Reason for such postponement or delay no longer exists, in each case, promptly after
the occurrence thereof. In addition, the Company shall not be required to effect any registration
pursuant to Section 5(a), (i) within ninety (90) days after the effective date of any other
Registration Statement of the Company (other than a Registration Statement on Form S-4 or S-8 or
any successor form thereto) or (ii) if Form S-3 is not available for such offering by the S-3
Initiating Holders.

               (d) Expenses. Except as provided in Section 8(d), the Company shall bear all
Registration Expenses in connection with any S-3 Registration pursuant to this Section 5, whether
or not such S-3 Registration becomes effective.

               (e) Automatic Shelf Registration Statement. After the Registration Statement with
respect to a S-3 Registration that is an Automatic Shelf Registration Statement becomes effective,
upon written request by the S-3 Initiating Holders, the Company shall, as promptly as practicable
after receiving such request,

13

 

(i) file with the Commission a prospectus supplement naming the S-3 Participating Stockholders
as selling stockholders and the amount of Registrable Securities to be offered and to include, to
the extent not included or incorporated by reference in the Registration Statement, any other
information omitted from the Prospectus used in connection with such Registration Statement as
permitted by Rule 430B promulgated under the Securities Act (including the plan of distribution)
and (ii) to pay any necessary filing fees within the time period required.

          6. Hedging Transactions.

               (a) In any S-3 Registration, the S-3 Initiating Holders may elect to disclose their intention
to engage in Hedging Transactions. The Company agrees that, in connection with any proposed
Hedging Transaction, if, in the reasonable judgment of Designated Stockholders’ Counsel (after
good-faith consultation with counsel to the Company), it is necessary or desirable to register
under the Securities Act such Hedging Transaction or sales or transfers (whether short or long) of
Registrable Securities in connection therewith, then the Company shall use its commercially
reasonable efforts to take such actions (which may include, among other things, the filing of a
prospectus supplement or post-effective amendment to a Registration Statement to include additional
or changed information that is material or is otherwise required to be disclosed, including,
without limitation, a description of such Hedging Transaction, the name of the Hedging
Counterparty, identification of the Hedging Counterparty or its Affiliates as underwriters or
potential underwriters, if applicable, or any change to the plan of distribution) as may reasonably
be required to register such Hedging Transaction or sales or transfers of Registrable Securities in
connection therewith under the Securities Act in a manner consistent with the rights and
obligations of the Company hereunder with respect to the registration of Registrable Securities.
Any information regarding the Hedging Transaction included in a Registration Statement, Prospectus
or Free Writing Prospectus pursuant to this Section 6(a) shall, for purposes of Section 9, be
deemed to be information provided by the Designated Stockholder that is party to such Hedging
Transaction and is selling Registrable Securities pursuant to such Registration Statement for
purposes of Section 9.

               (b) The selection of any Hedging Counterparty shall not be subject to Section 3(f), but the
Hedging Counterparty shall be selected by the Designated Stockholders holding a majority of the
Registrable Securities subject to the Hedging Transaction that are proposed to be included in such
Registration Statement.

               (c) If in connection with a Hedging Transaction, a Hedging Counterparty or any Affiliate
thereof is (or may be considered) an underwriter or selling stockholder, then it shall be required
to provide customary indemnities to the Company regarding the plan of distribution and like
matters.

               (d) The Company further agrees to include, under the caption “Plan of Distribution” (or the
equivalent caption), in each Registration Statement and any related Prospectus (to the extent such
inclusion is permitted under applicable Commission regulations and is consistent with comments
received from the Commission

14

 

during any Commission review of the Registration Statement), language substantially in the
form of Annex B hereto and to include in each Prospectus supplement filed in connection with any
proposed Hedging Transaction language mutually agreed upon by the Company, the relevant Designated
Stockholder and the Hedging Counterparty describing such Hedging Transaction.

          7. Holdback Agreements.

               (a) Restrictions on Public Sale by Designated Stockholders.

                    (i) To the extent requested by the Approved Underwriter or the Company Underwriter, as the
case may be, in the case of an underwritten offering, each Designated Stockholder, agrees (x) not
to effect any public sale or distribution of any Registrable Securities or of any securities
convertible into or exchangeable or exercisable for such Registrable Securities, including a sale
pursuant to Rule 144 (or any successor rule or regulation) promulgated under the Securities Act, or
offer to sell, contract to sell (including, without limitation, any short sale), grant any option
to purchase or enter into any hedging or similar transaction with the same economic effect as a
sale of any Registrable Securities and (y) except as otherwise consented to by the Company, not to
make any request for a Demand Registration or S-3 Registration under this Agreement, in each case,
during the period beginning on the effective date of any Registration Statement relating to a
registration in which Designated Stockholders of Registrable Securities are participating and
ending on the ninetieth (90th) day following the actual effective date of such
Registration Statement (except as part of such registration); provided, however, that any waiver or
exception from these provisions with respect to a Designated Stockholder by the Company, any
Approved Underwriter or any Company Underwriter shall automatically apply to all Designated
Stockholders.

                    (ii) The Designated Stockholders hereby agree that they shall act in good faith with respect
to the restrictions set forth in Section 7(a) and shall take no action or omit to take any action
with the intention of circumventing or evading the restrictions applicable to them under this 7(a).

               (b) Restrictions on Public Sale by the Company. Unless the Company shall have
received the prior written consent of the Designated Stockholders holding at least a majority of
the Registrable Securities, the Company agrees not to (i) effect any public sale or distribution of
any of its securities, or any securities convertible into or exchangeable or exercisable for such
securities (except pursuant to registrations on Form S-4 or S-8 or any successor form thereto),
(ii) file any Registration Statements relating to the registration of securities for the Company’s
account (except pursuant to registrations on Form S-4 or S-8 or any successor form thereto), or
(iii) make any public announcements related to clause (i) or (ii), in each case, during the period
beginning on the effective date of any Registration Statement relating to a registration in which
the Designated Stockholders of Registrable Securities are participating and ending on the earlier
of (X) the date on which all Registrable Securities registered on such Registration Statement are
sold and (Y) sixty (60) days after the actual effective date of such Registration Statement (except
as part of such registration); provided in the case of clause

15

 

(Y) that such period shall be extended by the total number of days that such period is
interrupted by a postponement pursuant to Section 3(a) or Section 5(c), as applicable.

          8. Registration Procedures.

               (a) Obligations of the Company. Whenever registration of Registrable Securities has
been requested or required pursuant to Section 3, Section 4 or Section 5, the Company shall use its
commercially reasonable efforts to effect the registration and sale of such Registrable Securities
in accordance with the intended method of distribution thereof as promptly as practicable, and in
connection with any such request, the Company shall:

                    (i) as promptly as practicable, prepare and file with the Commission a Registration Statement
on any form for which the Company then qualifies or which counsel for the Company shall deem
appropriate and which form shall be available for the sale of such Registrable Securities in
accordance with the intended method of distribution thereof, and cause such Registration Statement
to become effective; provided, however, that (x) before filing a Registration
Statement or Prospectus or any amendments or supplements thereto (including, without limitation,
any documents incorporated by reference therein), or before using any Free Writing Prospectus, the
Company shall provide one firm of legal counsel selected by the Designated Stockholders holding a
majority of the Registrable Securities being registered in such registration (“Designated
Stockholders’ Counsel”) and any other Inspector with an opportunity to review and comment on
such Registration Statement and each Prospectus included therein (and each amendment or supplement
thereto) and each Free Writing Prospectus to be filed with the Commission, subject to such
documents being under the Company’s control (it being understood that the Company shall not file a
Registration Statement, any Prospectus, any Free Writing Prospectus or any amendments or
supplements thereto to which the Designated Stockholders’ Counsel shall reasonably object in good
faith), and (y) the Company shall notify the Designated Stockholders’ Counsel and each seller of
Registrable Securities pursuant to such Registration Statement of any stop order issued or
threatened by the Commission, including any stop order suspending the effectiveness of a
Registration Statement covering any Registrable Securities, and, subject to Sections 3(a) and 5(c),
take all reasonable actions to avoid the issuance of, or, if issued, obtain the withdrawal of (A)
any such stop order suspending the effectiveness of a Registration Statement or (B) any suspension
of the qualification (or exemption from qualification) of any of the Registrable Securities for
sale in any jurisdiction, as promptly as practicable, including, without limitation, the filing of
any amendments and supplements to such Registration Statement and the Prospectus used in connection
therewith;

                    (ii) as promptly as practicable, prepare and file with the Commission such amendments and
supplements to such Registration Statement and the Prospectus used in connection therewith as may
be necessary to respond to comments received by the Company from the Commission with respect to the
Registration Statement and to keep such Registration Statement effective for the lesser of (x)  the
time period provided for in Section 3(c), (y) the period after which the entire amount of all such
Registrable Securities registered under such Registration Statement could not be

16

 

sold in a single sale, in the opinion of counsel reasonably satisfactory to the Company and
such Designated Stockholder, without any limitation as to volume pursuant to Rule 144 (or any
successor rule or regulation) under the Securities Act (or, in the case of an S-3 Registration,
three years from the effective date of the Registration Statement if such Registration Statement is
filed pursuant to Rule 415 promulgated under the Securities Act (or any successor rule or
regulation)) and (z) such shorter period which will terminate when all Registrable Securities
covered by such Registration Statement have been sold or otherwise cease to be Registrable
Securities (or, if such Registration Statement is an Automatic Shelf Registration Statement, if
shorter, on the third anniversary of the date of filing of such Automatic Shelf Registration
Statement); and (B) comply with the provisions of the Securities Act with respect to the
disposition of all securities covered by such Registration Statement during such period in
accordance with the intended methods of disposition by the sellers thereof set forth in such
Registration Statement;

                    (iii) as promptly as practicable, furnish to each seller of Registrable Securities such number
of copies of such Registration Statement, each amendment and supplement thereto (in each case
including all exhibits thereto), the Prospectus included in such Registration Statement (including
each preliminary Prospectus), any Prospectus filed under Rule 424 under the Securities Act and any
Free Writing Prospectus as each such seller may reasonably request in order to facilitate the
disposition of the Registrable Securities owned by such seller;

                    (iv) as promptly as practicable, register or qualify such Registrable Securities under such
other securities or “blue sky” laws of such jurisdictions as any seller of Registrable Securities
may reasonably request, and to continue such registration or qualification in effect in such
jurisdiction for as long as permissible pursuant to the laws of such jurisdiction, or for as long
as any such seller requests or until all of such Registrable Securities are sold, whichever is
shortest, and do any and all other acts and things which may be reasonably necessary or advisable
to enable any such seller to consummate the disposition in such jurisdictions of the Registrable
Securities owned by such seller; provided, however, that the Company shall not be
required to (x) qualify generally to do business in any jurisdiction where it would not otherwise
be required to qualify but for this Section 8(a)(iv), (y) subject itself to taxation in any such
jurisdiction or (z) consent to general service of process in any such jurisdiction;

                    (v) as promptly as practicable following its actual knowledge thereof, notify each seller of
Registrable Securities: (A) when a Prospectus, any Prospectus supplement, any Free Writing
Prospectus, a Registration Statement or a post-effective amendment to a Registration Statement has
been filed with the Commission, and, with respect to a Registration Statement or any post-effective
amendment, when the same has become effective; (B) of any request by the Commission or any other
federal or state governmental authority for amendments or supplements to a Registration Statement,
related Prospectus or Free Writing Prospectus or for additional information; (C) when the
Commission notifies the Company whether there will be a “review” of such Registration Statement and
whenever the Commission comments in writing on such Registration Statement (in which case the
Company shall provide true

17

 

and complete copies thereof and all written responses thereto to the Designated Stockholders’
Counsel); (D) of the receipt by the Company of any notification with respect to the suspension of
the qualification or exemption from qualification of any of the Registrable Securities for sale in
any jurisdiction or the initiation or threatening of any proceedings for such purpose; and (E) of
the existence of any fact or happening of any event of which the Company has knowledge which makes
any statement of a material fact in such Registration Statement, related Prospectus or Free Writing
Prospectus or any document incorporated or deemed to be incorporated therein by reference untrue or
which would require the making of any changes in the Registration Statement, Prospectus or Free
Writing Prospectus in order that, in the case of the Registration Statement, it will not contain
any untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary to make the statements therein not misleading, and that in the case of such
Prospectus or Free Writing Prospectus, it will not contain any untrue statement of a material fact
or omit to state any material fact required to be stated therein or necessary to make the
statements therein, in the light of the circumstances under which they were made, not misleading;

                    (vi) as promptly as practicable, upon the occurrence of any event contemplated by
Section 8(a)(v)(E) or, subject to Sections 3(a) and 5(c), the existence of a Valid Business Reason,
as promptly as practicable, prepare a supplement or amendment to such Registration Statement,
related Prospectus or Free Writing Prospectus and furnish to each seller of Registrable Securities
a reasonable number of copies of such supplement to or an amendment of such Registration Statement,
Prospectus or Free Writing Prospectus as may be necessary so that, after delivery to the purchasers
of such Registrable Securities, in the case of the Registration Statement, it will not contain any
untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary to make the statements therein not misleading, and that in the case of such
Prospectus or Free Writing Prospectus, it will not contain any untrue statement of a material fact
or omit to state any material fact required to be stated therein or necessary to make the
statements therein, in light of the circumstances under which they were made, not misleading;

                    (vii) enter into and perform customary agreements (including an underwriting agreement in
customary form with the Approved Underwriter or Company Underwriter, if any, selected as provided
in Section 3, Section 4 or Section 5, as the case may be) and take such other actions as are
reasonably required in order to expedite or facilitate the disposition of such Registrable
Securities and shall provide all reasonable cooperation, including causing its appropriate officers
to attend and participate in “road shows” and other information meetings organized by the Approved
Underwriter or Company Underwriter, if applicable, and causing counsel to the Company to deliver
customary legal opinions in connection with any such underwriting agreements;

                    (viii) make available at reasonable times for inspection by any, managing underwriter or
broker/dealer participating in any disposition of such Registrable Securities pursuant to a
Registration Statement, any attorney retained by any such managing underwriter or broker/dealer and
Designated Stockholders’ Counsel

18

 

(each, an “Inspector” and collectively, the “Inspectors”), all financial and
other records, pertinent corporate documents and properties of the Company and its subsidiaries
(collectively, the “Records”) as shall be reasonably necessary to enable them to exercise
their due diligence responsibility, and cause the Company’s and its subsidiaries’ officers,
directors and employees, and the Company’s independent registered public accounting firm, to make
themselves reasonably available to discuss the business of the Company and to supply all
information reasonably requested by any such Inspector in connection with such Registration
Statement. Records that the Company determines, in good faith, to be confidential and which it
notifies the Inspectors are confidential shall not be disclosed by the Inspectors (and the
Inspectors shall confirm their agreement in writing in advance to the Company if the Company shall
so request) unless (x) the disclosure of such Records is necessary, in the Company’s reasonable
judgment, to avoid or correct a misstatement or omission in the Registration Statement, (y) the
release of such Records is ordered pursuant to a subpoena or other order from a court of competent
jurisdiction after exhaustion of all appeals therefrom or (z) the information in such Records was
known to the Inspectors on a non-confidential basis prior to its disclosure by the Company or has
been made generally available to the public. Each seller of Registrable Securities agrees that it
shall, upon learning that disclosure of such Records is sought in a court of competent
jurisdiction, give notice to the Company and allow the Company, at the Company’s expense, to
undertake appropriate action to prevent disclosure of the Records deemed confidential. In the
event that the Company is unsuccessful in preventing the disclosure of such Records, such seller
agrees that it shall furnish only portion of those Records which it is advised by counsel is
legally required and shall exercise all reasonable efforts to obtain reliable assurance that
confidential treatment will be accorded to those Records;

                    (ix) if such sale is pursuant to an underwritten offering, obtain a “cold comfort” letter
dated the effective date of the Registration Statement and the date of the closing under the
underwriting agreement from the Company’s independent registered public accounting firm in
customary form and covering such matters of the type customarily covered by “cold comfort” letters
as the managing underwriter reasonably requests;

                    (x) furnish, at the request of any seller of Registrable Securities on the date such
securities are delivered to the underwriters for sale pursuant to such registration or, if such
securities are not being sold through underwriters, on the date the Registration Statement with
respect to such securities becomes effective, an opinion, dated such date, of counsel representing
the Company for the purposes of such registration, addressed to the underwriters, if any, and to
the seller making such request, covering such legal matters with respect to the registration in
respect of which such opinion is being given as the underwriters, if any, and such seller may
reasonably request and are customarily included in such opinions;

                    (xi) comply with all applicable rules and regulations of the Commission, and make available to
its security holders, as soon as reasonably practicable but no later than fifteen (15) months after
the effective date of the Registration Statement, an earnings statement covering a period of twelve
(12) months

19

 

beginning after the effective date of the Registration Statement, in a manner which satisfies
the provisions of Section 11(a) of the Securities Act and Rule 158 thereunder;

                    (xii) cause all such Registrable Securities to be listed on each securities exchange on which
similar securities issued by the Company are then listed, provided that the applicable
listing requirements are satisfied and it being understood that the Company shall not be required
to list any class of securities on an exchange if the class is not then currently listed;

                    (xiii) cooperate with each seller of Registrable Securities and each underwriter participating
in the disposition of such Registrable Securities and their respective counsel in connection with
any filings required to be made with FINRA;

                    (xiv) use its commercially reasonable efforts to cause the Registrable Securities covered by
such Registration Statement to be registered with or approved by such other governmental agencies
or authorities, as may be reasonably necessary by virtue of the business and operations of the
Company to enable the seller or sellers of Registrable Securities to consummate the disposition of
such Registrable Securities; and

                    (xv) take all other steps reasonably necessary to effect the registration of the Registrable
Securities contemplated hereby and reasonably cooperate with the holders of such Registrable
Securities to facilitate the disposition of such Registrable Securities pursuant thereto;

                    (xvi) as promptly as practicable and within the deadlines specified by the Securities Act,
make all required filings of all Prospectuses and Free Writing Prospectuses with the Commission;

                    (xvii) as promptly as practicable and within the deadlines specified by the Securities Act,
make all required filing fee payments in respect of any Registration Statement or Prospectus used
under this Agreement (and any offering covered thereby); and

                    (xviii) keep the Designated Stockholder’s Counsel advised with respect to the progress of any
registration statement hereunder and any material related issues.

               (b) Seller Requirements. In connection with any offering under any Registration
Statement under this Agreement, each Designated Stockholder (i) shall promptly furnish to the
Company in writing (including email correspondence) such information with respect to such
Designated Stockholder and the intended method of disposition of its Registrable Securities as the
Company may reasonably request or as may be required by law for use in connection with any related
Registration Statement or Prospectus (or amendment or supplement thereto) and all information
required to be disclosed in order to make the information previously furnished to the Company by
such Designated Stockholder not contain a material misstatement of fact or necessary to cause such
Registration Statement or Prospectus (or amendment or supplement thereto) not to

20

 

omit a material fact with respect to such Designated Stockholder necessary in order to make
the statements therein not misleading; (ii) shall comply with the Securities Act and the Exchange
Act and all applicable state securities laws and comply with all applicable regulations in
connection with the registration and the disposition of the Registrable Securities; and (iii) shall
not use any Free Writing Prospectus without the prior written consent of the Company. If any
seller of Registrable Securities fails to provide such information required to be included in such
Registration Statement by applicable securities laws or otherwise reasonably necessary in
connection with the disposition of such Registrable Securities in a timely manner after written
request therefor, the Company may exclude such seller’s Registrable Securities from a registration
under Sections 3, 4 or 5 hereof.

               (c) Notice to Discontinue. Each Designated Stockholder agrees that, upon receipt of
any notice from the Company of the happening of any event of the kind described in
Section 8(a)(v)(D) or, subject to Section 3(a) and 5(c), the existence of Valid Business Reason,
such Designated Stockholder shall forthwith discontinue disposition of Registrable Securities
pursuant to the Registration Statement covering such Registrable Securities until such Designated
Stockholder’s receipt of the copies of the supplemented or amended Prospectus or Free Writing
Prospectus contemplated by Section 8(a)(vi) (or if no supplemental or amended prospectus or Free
Writing Prospectus is required, upon confirmation from the Company that use of the Prospectus or
Free Writing Prospectus is once again permitted) and, if so directed by the Company, such
Designated Stockholder shall deliver to the Company (at the Company’s expense) all copies, other
than permanent file copies then in such Designated Stockholder’s possession, of the Prospectus or
Free Writing Prospectus covering such Registrable Securities which is current at the time of
receipt of such notice. If the Company shall give any such notice, the Company shall extend the
period during which such Registration Statement shall be maintained effective pursuant to this
Agreement (including, without limitation, the period referred to in Section 8(a)(ii)) by the number
of days during the period from and including the date of the giving of such notice pursuant to
Section 8(a)(v)(D) to and including the date when sellers of such Registrable Securities under such
Registration Statement shall have received the copies of the supplemented or amended Prospectus or
Free Writing Prospectus contemplated by and meeting the requirements of Section 8(a)(v).

               (d) Registration Expenses. The Company shall pay all expenses arising from or
incident to its performance of, or compliance with, this Agreement, including, without limitation,
(i) Commission, stock exchange and FINRA registration and filing fees, (ii) all fees and expenses
incurred in complying with state securities or “blue sky” laws (including reasonable fees, charges
and disbursements of counsel to any underwriter incurred in connection with “blue sky”
qualifications of the Registrable Securities as may be set forth in any underwriting agreement),
(iii) all printing, messenger and delivery expenses, (iv) the fees, charges and expenses of counsel
to the Company and of its independent registered public accounting firm and any other accounting
fees, charges and expenses incurred by the Company (including, without limitation, any expenses
arising from any “cold comfort” letters or any special audits incident to or required by any
registration or qualification) and (v) any liability insurance

21

 

or other premiums for insurance obtained in connection with any Demand Registration or
piggy-back registration thereon, Incidental Registration or S-3 Registration pursuant to the terms
of this Agreement, regardless of whether such Registration Statement is declared effective. All of
the expenses described in the preceding sentence of this Section 8(d) are referred to herein as
“Registration Expenses.” The Designated Stockholders shall (A) bear (x) the expense of any
broker’s commission or underwriter’s discount or commission relating to registration and sale of
such Designated Stockholders’ Registrable Securities and (y) the fees and expenses of their own
counsel and (B) reimburse the Company for the first $55,000 of Registration Expenses incurred by
the Company, pro rata according to each Designated Stockholder’s participation in the registered
offering giving rise to such Registration Expenses.

          9. Indemnification; Contribution.

               (a) Indemnification by the Company. The Company agrees to indemnify and hold harmless
each Designated Stockholder, its partners, directors, officers, Affiliates, stockholders, members,
employees, trustees and agents and each Person who controls (within the meaning of Section 15 of
the Securities Act) such Designated Stockholder and the partners, directors, officers, Affiliates,
stockholders, members, employees, trustees and agents of such controlling Person, from and against
any and all losses, claims, damages, liabilities and expenses, or any action or proceeding, whether
commenced or threatened, in respect thereof (including reasonable costs of investigation and
reasonable attorneys’ fees and expenses) (each, a “Liability” and collectively,
“Liabilities”), arising out of or based upon (i) any untrue, or allegedly untrue, statement
of a material fact contained in the Disclosure Package, the Registration Statement, the Prospectus,
any Free Writing Prospectus or in any amendment or supplement thereto; (ii) the omission or alleged
omission to state in the Disclosure Package, the Registration Statement, the Prospectus, any Free
Writing Prospectus or in any amendment or supplement thereto any material fact required to be
stated therein or necessary to make the statements therein not misleading under the circumstances
such statements were made and (iii) any violation or alleged violation by the Company of the
Securities Act, the Exchange Act or any federal or state securities law in connection with the
offering covered by such Registration Statement; provided, however, that the Company shall not be
held liable in any such case to the extent that any such Liability arises out of or is based upon
an untrue statement or alleged untrue statement or omission or alleged omission contained in such
Disclosure Package, Registration Statement, Prospectus, Free Writing Prospectus or such amendment
or supplement thereto in reliance upon and in strict conformity with information concerning such
Designated Stockholder furnished in writing to the Company by or on behalf of such Designated
Stockholder expressly for use in such Disclosure Package, Registration Statement, Prospectus, Free
Writing Prospectus or such amendment or supplement thereto, including, without limitation, the
information furnished to the Company pursuant to Section 8(b). The Company shall also provide
customary indemnities to any underwriters, selling brokers, dealer managers and similar securities
industry professionals participating in any distribution pursuant hereto, including their officers,
directors and employees and each Person who controls such underwriters (within the

22

 

meaning of Section 15 of the Securities Act) to the same extent as provided above with respect
to the indemnification of the Designated Stockholders of Registrable Securities.

               (b) Indemnification by Designated Stockholders. In connection with any offering in
which a Designated Stockholder is participating pursuant to Section 3, 4 or 5, such Designated
Stockholder agrees severally to indemnify and hold harmless the Company, the other Designated
Stockholders, any underwriter retained by the Company and each Person who controls the Company, the
other Designated Stockholders or such underwriter (within the meaning of Section 15 of the
Securities Act) to the same extent as the indemnity from the Company to the Designated Stockholders
(including indemnification of their respective partners, directors, officers, members, employees
and trustees) set forth in Section 9(a)(i), (ii) and (iii) above, but only to the extent that
Liabilities arise out of or are based upon a statement or alleged statement or an omission or
alleged omission that was made in reliance upon and in strict conformity with information with
respect to such Designated Stockholder furnished in writing to the Company by or on behalf of such
Designated Stockholder expressly for use in such Disclosure Package, Registration Statement,
Prospectus, Free Writing Prospectus or such amendment or supplement thereto, including, without
limitation, the information furnished to the Company pursuant to Section 8(b); provided,
however, that the total amount to be indemnified by such Designated Stockholder pursuant to
this Section 9(b) shall be limited to the net proceeds received by such Designated Stockholder in
the offering to which such Disclosure Package, Registration Statement, Prospectus, Free Writing
Prospectus or such amendment or supplement thereto relates.

               (c) Conduct of Indemnification Proceedings. Any Person entitled to indemnification or
contribution hereunder (the “Indemnified Party”) agrees to give prompt written notice to
the indemnifying party (the “Indemnifying Party”) after the receipt by the Indemnified
Party of any written notice of the commencement of any action, suit, proceeding or investigation or
threat thereof made in writing for which the Indemnified Party intends to claim indemnification or
contribution pursuant to this Agreement; provided, however, that the failure to so
notify the Indemnifying Party shall not relieve the Indemnifying Party of any Liability that it may
have to the Indemnified Party hereunder (except to the extent that the Indemnifying Party is
materially prejudiced or otherwise forfeits substantive rights or defenses by reason of such
failure). If notice of commencement of any such action is given to the Indemnifying Party as above
provided, the Indemnifying Party shall be entitled to participate in and, to the extent it may
wish, jointly with any other Indemnifying Party similarly notified, to assume the defense of such
action at its own expense, with counsel chosen by it and reasonably satisfactory to such
Indemnified Party. Each Indemnified Party shall have the right to employ separate counsel in any
such action and participate in the defense thereof, but the fees and expenses of such counsel shall
be paid by the Indemnified Party unless (i) the Indemnifying Party agrees to pay the same, (ii) the
Indemnifying Party fails to promptly assume the defense of such action and to employ counsel
reasonably satisfactory to the Indemnified Party or (iii) the named parties to any such action
(including any impleaded parties) include both the Indemnifying Party and the Indemnified Party and
such parties have been advised by such counsel that either (x) representation of such Indemnified
Party and the Indemnifying Party by the same counsel would be inappropriate under

23

 

applicable standards of professional conduct or (y) there may be one or more legal defenses
available to the Indemnified Party which are different from or additional to those available to the
Indemnifying Party. In any of such cases, the Indemnifying Party shall not have the right to
assume the defense of such action on behalf of such Indemnified Party, it being understood,
however, that the Indemnifying Party shall not be liable for the reasonable fees and expenses of
more than one separate firm of attorneys (in addition to any local counsel) for all Indemnified
Parties and all such expenses shall be reimbursed as incurred. No Indemnifying Party shall be
liable for any settlement entered into without its written consent, which consent shall not be
unreasonably withheld. No Indemnifying Party shall, without the consent of such Indemnified Party,
effect any settlement of any pending or threatened proceeding in respect of which such Indemnified
Party is a party and indemnity has been sought hereunder by such Indemnified Party, unless such
settlement includes an unconditional release of such Indemnified Party from all liability for
claims that are the subject matter of such proceeding. Notwithstanding the foregoing, if at any
time an Indemnified Party shall have requested the Indemnifying Party to reimburse the Indemnified
Party for fees and expenses of counsel as contemplated by this Section 9, the Indemnifying Party
agrees that it shall be liable for any settlement of any proceeding effected without the
Indemnifying Party’s written consent if (i) such settlement is entered into more than thirty (30)
Business Days after receipt by the Indemnifying Party of the aforesaid request and (ii) the
Indemnifying Party shall not have reimbursed the Indemnified Party in accordance with such request
or contested the reasonableness of such fees and expenses prior to the date of such settlement.

               (d) Contribution. If the indemnification provided for in this Section 9 from the
Indemnifying Party is unavailable to an Indemnified Party hereunder or insufficient to hold
harmless an Indemnified Party in respect of any Liabilities referred to herein, then each
Indemnifying Party, in lieu of indemnifying such Indemnified Party, shall contribute to the amount
paid or payable by such Indemnified Party as a result of such Liabilities in such proportion as is
appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in
connection with the actions which resulted in such Liabilities, as well as any other relevant
equitable considerations. The relative faults of such Indemnifying Party and Indemnified Party
shall be determined by reference to, among other things, whether any action in question, including
any untrue or alleged untrue statement of a material fact or omission or alleged omission to state
a material fact, has been made by, or relates to information supplied by, such Indemnifying Party
or Indemnified Party, and the parties’ relative intent, knowledge, access to information and
opportunity to correct or prevent such action. The amount paid or payable by a party as a result
of the Liabilities referred to above shall be deemed to include, subject to the limitations set
forth in Sections 9(a), 9(b) and 9(c), any legal or other fees, charges or expenses reasonably
incurred by such party in connection with any investigation or proceeding; provided, that
the total amount to be contributed by any Designated Stockholder shall be limited to the amount by
which the net proceeds (after deducting the underwriters’ discounts and commissions) received by
such Designated Stockholder in the offering exceed the amount of any damages that the Designated
Stockholder has otherwise been required to pay by reason of such untrue or alleged untrue statement
or omission or alleged omission.

24

 

          The parties hereto agree that it would not be just and equitable if contribution pursuant to
this Section 9(d) were determined by pro rata allocation or by any other method of allocation which
does not take account of the equitable considerations referred to in the immediately preceding
paragraph. No Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f)
of the Securities Act) shall be entitled to contribution from any Person who was not guilty of such
fraudulent misrepresentation.

          10. Rule 144. The Company covenants that it shall use its commercially reasonable
efforts to take such action as may be required from time to time (including, without limitation,
make and keep public information regarding the Company available, as those terms are understood and
defined in Rule 144 under the Securities Act) to enable such Designated Stockholder to sell
Registrable Securities without registration under the Securities Act within the limitation of the
exemptions provided by (i) Rule 144 under the Securities Act, as such rule may be amended from time
to time, or (ii) any similar rules or regulations hereafter adopted by the Commission. The Company
shall, upon the request of any Designated Stockholder, deliver to such Designated Stockholder a
written statement as to whether it has complied with such requirements.

          11. Miscellaneous.

               (a) Stock Splits, etc. The provisions of this Agreement shall be appropriately
adjusted for any stock dividends, splits, reverse splits, combinations recapitalizations and the
like occurring after the date hereof. The Company shall cause any successor or assign (whether by
merger, consolidation, sale of assets or otherwise) to enter into a new registration rights
agreement with the Designated Stockholders on terms substantially the same as this Agreement as a
condition of any such transaction.

               (b) No Inconsistent Agreements. The Company hereby represents and warrants that it
has not previously entered into any agreement granting registration rights to any Person with
respect to any securities of the Company. The Company shall not enter into any agreement with
respect to its securities that is inconsistent with the rights granted to the Designated
Stockholders in this Agreement or grant any additional registration rights to any Person or with
respect to any securities that are not Registrable Securities which rights are inconsistent with
the rights granted in this Agreement.

               (c) Remedies. The Designated Stockholders, in addition to being entitled to exercise
all rights granted by law, including recovery of damages, shall be entitled to specific performance
of their rights under this Agreement. The Company agrees that monetary damages would not be
adequate compensation for any loss incurred by reason of a breach by it of the provisions of this
Agreement and hereby agrees to waive in any action for specific performance the defense that a
remedy at law would be adequate.

               (d) Amendments and Waivers. Except as otherwise provided herein, the provisions of
this Agreement may not be amended, modified or supplemented,

25

 

and waivers or consents to departures from the provisions hereof may not be given unless
consented to in writing by the Company and the Designated Stockholders holding at least a majority
of the Registrable Securities; provided, however, that no amendment, modification,
supplement, waiver or consent to depart from the provisions hereof shall be effective if such
amendment, modification, supplement, waiver or consent to depart from the provisions hereof
materially and adversely affects the substantive rights or obligations of one Designated
Stockholder, or group of Designated Stockholders, without a similar and proportionate effect on the
substantive rights or obligations of all Designated Stockholders, unless each such
disproportionately affected Designated Stockholder consents in writing thereto.

               (e) Notices. All notices, demands and other communications provided for or permitted
hereunder shall be made in writing and shall be made by registered or certified first-class mail,
return receipt requested, telecopy, electronic transmission, courier service or personal delivery:

                    (i)      If to the Company:

	 	 	 	Sun-Times Media Group, Inc.

350 N. Orleans St.

Chicago, Il 60654

Telecopy:

Attention: General Counsel
	 
	 	 	 	with a copy to:
	 
	 	 	 	Paul, Weiss, Rifkind, Wharton & Garrison LLP

1285 Avenue of the Americas

New York, New York 10019-6064

Telecopy: (212) 757-3990

Attention: Judith R. Thoyer

                    (ii)      If to any Designated Stockholder, at its address as
it appears in the books and records of the Company;
provided that if Hollinger Inc. and/or 4322525 Canada
Inc. is a Designated Stockholder, then a copy of any
communication shall also be sent to the Indenture
Trustees at the following addresses:

	 	 	 	Delaware Trust Company, National Association

c/o Wachovia Bank, National Association

123 S. Broad Street, 9th Floor

Philadelphia, PA 19109

Attention: Ms. Mary M. McCracken
	 
	 	 	 	HSBC Bank USA, National Association

Corporate Trust & Loan Agency

452 Fifth Avenue

New York, NY 10018

Attention: Ms. Sandra E. Horwitz

26

 

          All such notices, demands and other communications shall be deemed to have been duly given
when delivered by hand, if personally delivered; when delivered by courier, if delivered by
commercial courier service; five (5) Business Days after being deposited in the mail, postage
prepaid, if mailed; and when receipt is acknowledged, if telecopied, or electronically transmitted.
Any party may by notice given in accordance with this Section 11(e) designate another address or
Person for receipt of notices hereunder.

               (f) Permitted Assignees; Third Party Beneficiaries. This Agreement shall inure to the
benefit of and be binding upon the permitted assignees of the parties hereto as provided in
Section 2(d). Except as provided in Section 9, no Person other than the parties hereto and their
permitted assignees is intended to be a beneficiary of this Agreement.

               (g) Counterparts. This Agreement may be executed in any number of counterparts and by
the parties hereto in separate counterparts, each of which when so executed shall be deemed to be
an original and all of which taken together shall constitute one and the same agreement.

               (h) Headings. The headings in this Agreement are for convenience of reference only
and shall not limit or otherwise affect the meaning hereof.

               (i) GOVERNING LAW. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE
WITH THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW
THEREOF.

               (j) Severability. If any one or more of the provisions contained herein, or the
application thereof in any circumstance, is held invalid, illegal or unenforceable in any respect
for any reason, the validity, legality and enforceability of any such provision in every other
respect and of the remaining provisions hereof shall not be in any way impaired.

               (k) Rules of Construction. Unless the context otherwise requires, references to
sections or subsections refer to sections or subsections of this Agreement. Terms defined in the
singular have a comparable meaning when used in the plural, and vice versa.

               (l) Entire Agreement. This Agreement is intended by the parties as a final expression
of their agreement and intended to be a complete and exclusive statement of the agreement and
understanding of the parties hereto with respect to the subject matter contained herein. There are
no restrictions, promises, representations, warranties or undertakings with respect to the subject
matter contained herein, other than those set forth or referred to herein. This Agreement
supersedes all prior agreements and understandings among the parties with respect to such subject
matter.

27

 

               (m) Further Assurances. Each of the parties shall execute such documents and perform
such further acts as may be reasonably required or desirable to carry out or to perform the
provisions of this Agreement.

               (n) Other Agreements. Nothing contained in this Agreement shall be deemed to be a
waiver of, or release from, any obligations any party hereto may have under, or any restrictions on
the transfer of Registrable Securities or other securities of the Company imposed by, any other
agreement or applicable law.

[Remainder of page intentionally left blank]

28

 

          IN WITNESS WHEREOF, the undersigned have executed, or have caused to be executed, this
Registration Rights Agreement on the date first written above.

	 	 	 	 	 
	 	Sun-Times Media Group, Inc.

 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 

	 	 	 	 	 
	 	Hollinger Inc.

 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 

	 	 	 	 	 
	 	4322525 Canada Inc.

 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 

 

 

Annex A

[Name and Address of Transferee/Pledgee]

                    

 [Address]

[Name and Address of Transferor/Pledgor]

                    , 200__

Ladies and Gentlemen:

          Reference is made to the Registration Rights Agreement, dated as of June 17, 2008 (the
“Registration Rights Agreement”), by and among Sun-Times Media Group, Inc., Hollinger Inc.,
4322525 Canada Inc., and certain additional stockholders referred to therein. All capitalized terms
used herein but not otherwise defined shall have the meanings given to them in the Registration
Rights Agreement.

          In connection with the [transfer][pledge] by [Name of Transferor/Pledgor] of Registrable
Securities with associated registration rights under the Registration Rights Agreement to [Name of
Transferee/Pledgee] as [transferee (the “Transferee”)][pledgee (the “Pledgee”)],
the [Transferee][Pledgee] hereby agrees to be bound as a Designated Stockholder by the provisions
of the Registration Rights Agreement as provided under Section 2(d)(i) thereto.

          [For transfers from Hollinger Inc. and 4322525 Canada Inc. to the Indenture Trustees] [Further
reference is made to the Indentures. Hollinger Inc. and 4322525 Canada Inc. hereby acknowledge and
agree to fund any amounts that the Indenture Trustees shall be obligated to pay as a Designated
Stockholder under the Registration Rights Agreement (including without limitation those amounts set
forth in Sections 8(d) and 9(b)); provided that Hollinger Inc. and 4322525 Canada Inc.,
collectively, shall only be obligated to fund up to $55,000 less any amounts paid or to be paid by
them to the Company pursuant to Section 8(d)(B). In addition, Hollinger Inc. and 4322525 Canada
Inc. hereby acknowledge that by agreeing to be bound by the Registration Rights Agreement as a
Designated Stockholder, the Indenture Trustees do not waive or surrender any of its rights under
the applicable Indenture (and related security agreement), including the right to be compensated,
reimbursed and indemnified in accordance with the terms of the applicable Indenture by Hollinger
Inc., any of the guarantors and/or the holders of the notes issued under such Indenture (and
related security agreement).]

          This consent shall be governed by New York law.

	 	 	 	 	 
	 	Yours sincerely,

[Name of Transferee/Pledgee]

 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 

2

 

Annex B

Plan of Distribution

                    A selling stockholder may also enter into hedging and/or monetization transactions. For
example, a selling stockholder may:

	 	•	 	enter into transactions with a broker-dealer or affiliate of a
broker-dealer or other third party in connection with which that
other party will become a selling stockholder and engage in short
sales of our common stock under this prospectus, in which case the
other party may use shares of our common stock received from the
selling stockholder to close out any short position;
	 
	 	•	 	sell short our common stock under this prospectus and use shares
of our common stock held by the selling stockholder to close out
any short position;
	 
	 	•	 	enter into options, forwards or other transactions that require
the selling stockholder to deliver, in a transaction exempt from
registration under the Securities Act, shares of our common stock
to a broker-dealer or an affiliate of a broker-dealer or other
third party who may then become a selling stockholder and publicly
resell or otherwise transfer shares of our common stock under this
prospectus;
	 
	 	•	 	enter into derivative transactions with third parties, or sell
securities not covered by this prospectus to third parties in
privately negotiated transactions. If the applicable prospectus
supplement indicates, in connection with those derivatives, the
third parties may sell securities covered by this prospectus and
the applicable prospectus supplement, including in short sale
transactions. If so, the third party may use securities pledged by
the selling stockholder or borrowed from the selling stockholder
or others to settle those sales or to close out any related open
borrowings of stock, and may use securities received from the
selling stockholder in settlement of those derivatives to close
out any related open borrowings of stock. The third party in such
sale transactions will be an underwriter and will be identified in
the applicable prospectus supplement (or a post effective
amendment).

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00146-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00146-of-00352.parquet"}]]